Trial Outcomes & Findings for A Safety and Efficacy Trial of JCAR017 Combinations in Subjects With Relapsed/Refractory B-cell Malignancies (NCT NCT03310619)
NCT ID: NCT03310619
Last Updated: 2024-04-04
Results Overview
Participants enrolled in Phase 1 are considered evaluable for DLTs if they received an infusion of conforming JCAR017 cell product and at least one dose of the combination agent and completed the specified DLT evaluation period or if they have received an infusion of conforming JCAR017 cell product and at least one dose of the combination agent and experience a DLT during the DLT evaluation period.
Recruitment status
COMPLETED
Study phase
PHASE1/PHASE2
Target enrollment
62 participants
Primary outcome timeframe
From first dose of the combination agent until 1 month (28 days) after JCAR017 infusion (pre- JCAR017 cohort) or from JCAR017 infusion until 1 month (28 days) after the first dose of combination agent (post-JCAR017 cohort)
Results posted on
2024-04-04
Participant Flow
Participants were only enrolled into the following groups: Arm A: Cohorts1 A and 1B, Arm B: Cohort 1A, Arm C: Cohort 1A, Arm D: Cohort 1A, Arm E: Cohort 1C, Arm F: Cohorts 1A and 1D.
Within each combination arm, up to 3 cohorts plus various sub cohorts (e.g., additional dose levels and schedules) may be tested. Data was pre-determined to be collected and reported combined as specified per arm and not per cohort.
Participant milestones
| Measure |
Arm A: Cohort 1A JCAR017 Plus Durvalumab (Post-JCAR017 Infusion)
JCAR017 was administered at a dose of (50 x 10\^6 CAR+ T cells). On Day 29 after infusion, Durvalumab was administered at a low dose. On day 43 after infusion Durvalumab was administered at a mid-dose and on days 57 and 85 after infusion was administered at a high dose. Participants who reached a partial response 3 months after JCAR017 infusion could continue Durvalumab until progression for a maximum total duration of 12 months.
|
Arm A: Cohort 1B JCAR017 Plus Durvalumab (Post-JCAR017 Infusion)
JCAR017 was administered at a dose of (100 x 10\^6 CAR+ T cells). On Day 29 after infusion, Durvalumab was administered at a low dose. On day 43 after infusion Durvalumab was administered at a mid-dose and on days 57 and 85 after infusion was administered at a high dose. Participants who reached a partial response 3 months after JCAR017 infusion could continue Durvalumab until progression for a maximum total duration of 12 months.
|
Arm B: Cohort 1A JCAR017 Plus CC-122 (Post-JCAR017 Infusion)
JCAR017 was administered at a dose of 100 x 10\^6 CAR+T cells. Between days 29 and 180 after infusion participants received a standard dose of CC-122, 5 out of 7 days. Participants who reached a partial response or stable disease 6 months (Day 180) after JCAR017 infusion could continue CC-122 until progression or for up to Month 24, whatever was earlier.
|
Arm C: Cohort 1A JCAR017 Plus CC-220 (Iberdomide) (Post-JCAR017 Infusion)
JCAR017 was administered at a dose of 100 x 10\^6 CAR+T cells. Between Days 15 -21 post infusion, CC-220 was administered at a standard dose. Participants who reached a partial response or stable disease at Day 85 (Month 3) after JCAR017 infusion could continue CC-220 until progression or for up to Month 12, whichever was earlier.
|
Arm D: Cohort 1A JCAR017 Plus Ibrutinib (Pre- and Post-JCAR017 Infusion)
Ibrutinib was administered from 35 days before to 85 days post JCAR017 infusion which was administered at a dose of 100 x 10\^6 CAR+T cells. Participants received ibrutinib until 85 days post-infusion (Month 3).
|
Arm E: Cohort 1C JCAR017 Plus Relatlimab and/or Nivolumab (Post-JCAR017 Infusion)
JCAR017 was administered at a dose of 100 x 10\^6 CAR+T cells. On days 8, 22, 36 post infusion, nivolumab was administered at a low dose. On days 57 and 85 post infusion, participants received nivolumab at a higher dose. Participants received nivolumab until Day 85 (Month 3).
|
Arm F: Cohort 1A Cohort 1A and 1D JCAR017 Plus CC-99282 (Post-JCAR017 Infusion)
JCAR017 was administered at a dose of (100 x 10\^6 CAR+ T cells). Starting on Day 8 post infusion, CC-99282 was administered every 7 days. Participants received CC-99282 until Day 85 (Month 3)
|
Arm F: Cohort 1D Cohort 1A and 1D JCAR017 Plus CC-99282 (Post-JCAR017 Infusion)
JCAR017 was administered at a dose of (100 x 10\^6 CAR+ T cells). Starting on Day 1 post infusion, CC-99282 was administered every 7 days. Participants received CC-99282 until Day 85 (Month 3)
|
|---|---|---|---|---|---|---|---|---|
|
Pre-Treatment Period
STARTED
|
11
|
9
|
13
|
1
|
17
|
2
|
7
|
2
|
|
Pre-Treatment Period
COMPLETED
|
8
|
8
|
11
|
1
|
16
|
2
|
5
|
2
|
|
Pre-Treatment Period
NOT COMPLETED
|
3
|
1
|
2
|
0
|
1
|
0
|
2
|
0
|
|
Treatment Period
STARTED
|
8
|
8
|
11
|
1
|
16
|
2
|
5
|
2
|
|
Treatment Period
Safety Set
|
8
|
8
|
11
|
1
|
17
|
2
|
4
|
2
|
|
Treatment Period
COMPLETED
|
6
|
5
|
4
|
0
|
12
|
2
|
3
|
0
|
|
Treatment Period
NOT COMPLETED
|
2
|
3
|
7
|
1
|
4
|
0
|
2
|
2
|
Reasons for withdrawal
| Measure |
Arm A: Cohort 1A JCAR017 Plus Durvalumab (Post-JCAR017 Infusion)
JCAR017 was administered at a dose of (50 x 10\^6 CAR+ T cells). On Day 29 after infusion, Durvalumab was administered at a low dose. On day 43 after infusion Durvalumab was administered at a mid-dose and on days 57 and 85 after infusion was administered at a high dose. Participants who reached a partial response 3 months after JCAR017 infusion could continue Durvalumab until progression for a maximum total duration of 12 months.
|
Arm A: Cohort 1B JCAR017 Plus Durvalumab (Post-JCAR017 Infusion)
JCAR017 was administered at a dose of (100 x 10\^6 CAR+ T cells). On Day 29 after infusion, Durvalumab was administered at a low dose. On day 43 after infusion Durvalumab was administered at a mid-dose and on days 57 and 85 after infusion was administered at a high dose. Participants who reached a partial response 3 months after JCAR017 infusion could continue Durvalumab until progression for a maximum total duration of 12 months.
|
Arm B: Cohort 1A JCAR017 Plus CC-122 (Post-JCAR017 Infusion)
JCAR017 was administered at a dose of 100 x 10\^6 CAR+T cells. Between days 29 and 180 after infusion participants received a standard dose of CC-122, 5 out of 7 days. Participants who reached a partial response or stable disease 6 months (Day 180) after JCAR017 infusion could continue CC-122 until progression or for up to Month 24, whatever was earlier.
|
Arm C: Cohort 1A JCAR017 Plus CC-220 (Iberdomide) (Post-JCAR017 Infusion)
JCAR017 was administered at a dose of 100 x 10\^6 CAR+T cells. Between Days 15 -21 post infusion, CC-220 was administered at a standard dose. Participants who reached a partial response or stable disease at Day 85 (Month 3) after JCAR017 infusion could continue CC-220 until progression or for up to Month 12, whichever was earlier.
|
Arm D: Cohort 1A JCAR017 Plus Ibrutinib (Pre- and Post-JCAR017 Infusion)
Ibrutinib was administered from 35 days before to 85 days post JCAR017 infusion which was administered at a dose of 100 x 10\^6 CAR+T cells. Participants received ibrutinib until 85 days post-infusion (Month 3).
|
Arm E: Cohort 1C JCAR017 Plus Relatlimab and/or Nivolumab (Post-JCAR017 Infusion)
JCAR017 was administered at a dose of 100 x 10\^6 CAR+T cells. On days 8, 22, 36 post infusion, nivolumab was administered at a low dose. On days 57 and 85 post infusion, participants received nivolumab at a higher dose. Participants received nivolumab until Day 85 (Month 3).
|
Arm F: Cohort 1A Cohort 1A and 1D JCAR017 Plus CC-99282 (Post-JCAR017 Infusion)
JCAR017 was administered at a dose of (100 x 10\^6 CAR+ T cells). Starting on Day 8 post infusion, CC-99282 was administered every 7 days. Participants received CC-99282 until Day 85 (Month 3)
|
Arm F: Cohort 1D Cohort 1A and 1D JCAR017 Plus CC-99282 (Post-JCAR017 Infusion)
JCAR017 was administered at a dose of (100 x 10\^6 CAR+ T cells). Starting on Day 1 post infusion, CC-99282 was administered every 7 days. Participants received CC-99282 until Day 85 (Month 3)
|
|---|---|---|---|---|---|---|---|---|
|
Pre-Treatment Period
Death
|
1
|
0
|
0
|
0
|
1
|
0
|
0
|
0
|
|
Pre-Treatment Period
Other reasons
|
2
|
1
|
2
|
0
|
0
|
0
|
2
|
0
|
|
Treatment Period
Death
|
1
|
2
|
0
|
0
|
1
|
0
|
2
|
0
|
|
Treatment Period
Adverse Event
|
0
|
1
|
4
|
1
|
0
|
0
|
0
|
0
|
|
Treatment Period
Withdrawal by participant
|
0
|
0
|
1
|
0
|
0
|
0
|
0
|
0
|
|
Treatment Period
Lost to Follow-up
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
1
|
|
Treatment Period
Study terminated by sponsor
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
1
|
|
Treatment Period
Physician Decision
|
0
|
0
|
0
|
0
|
3
|
0
|
0
|
0
|
|
Treatment Period
Other reasons
|
1
|
0
|
2
|
0
|
0
|
0
|
0
|
0
|
Baseline Characteristics
Race
Baseline characteristics by cohort
| Measure |
Arm A: Cohort 1A JCAR017 Plus Durvalumab (Post-JCAR017 Infusion)
n=11 Participants
JCAR017 was administered at a dose of (50 x 10\^6 CAR+ T cells). On Day 29 after infusion, Durvalumab was administered at a low dose. On day 43 after infusion Durvalumab was administered at a mid-dose and on days 57 and 85 after infusion was administered at a high dose. Participants who reached a partial response 3 months after JCAR017 infusion could continue Durvalumab until progression for a maximum total duration of 12 months.
|
Arm A: Cohort 1B JCAR017 Plus Durvalumab (Post-JCAR017 Infusion)
n=9 Participants
JCAR017 was administered at a dose of (100 x 10\^6 CAR+ T cells). On Day 29 after infusion, Durvalumab was administered at a low dose. On day 43 after infusion Durvalumab was administered at a mid-dose and on days 57 and 85 after infusion was administered at a high dose. Participants who reached a partial response 3 months after JCAR017 infusion could continue Durvalumab until progression for a maximum total duration of 12 months.
|
Arm B: Cohort 1A JCAR017 Plus CC-122 (Post-JCAR017 Infusion)
n=13 Participants
JCAR017 was administered at a dose of 100 x 10\^6 CAR+T cells. Between days 29 and 180 after infusion participants received a standard dose of CC-122, 5 out of 7 days. Participants who reached a partial response or stable disease 6 months (Day 180) after JCAR017 infusion could continue CC-122 until progression or for up to Month 24, whatever was earlier.
|
Arm C: Cohort 1A JCAR017 Plus CC-220 (Iberdomide) (Post-JCAR017 Infusion)
n=1 Participants
JCAR017 was administered at a dose of 100 x 10\^6 CAR+T cells. Between Days 15 -21 post infusion, CC-220 was administered at a standard dose. Participants who reached a partial response or stable disease at Day 85 (Month 3) after JCAR017 infusion could continue CC-220 until progression or for up to Month 12, whichever was earlier.
|
Arm D: Cohort 1A JCAR017 Plus Ibrutinib (Pre- and Post-JCAR017 Infusion)
n=17 Participants
Ibrutinib was administered from 35 days before to 85 days post JCAR017 infusion which was administered at a dose of 100 x 10\^6 CAR+T cells. Participants received ibrutinib until 85 days post-infusion (Month 3).
|
Arm E: Cohort 1C JCAR017 Plus Relatlimab and/or Nivolumab (Post-JCAR017 Infusion)
n=2 Participants
JCAR017 was administered at a dose of 100 x 10\^6 CAR+T cells. On days 8, 22, 36 post infusion, nivolumab was administered at a low dose. On days 57 and 85 post infusion, participants received nivolumab at a higher dose. Participants received nivolumab until Day 85 (Month 3).
|
Arm F: Cohort 1A Cohort 1A and 1D JCAR017 Plus CC-99282 (Post-JCAR017 Infusion)
n=7 Participants
JCAR017 was administered at a dose of (100 x 10\^6 CAR+ T cells). Starting on Day 8 post infusion, CC-99282 was administered every 7 days. Participants received CC-99282 until Day 85 (Month 3)
|
Arm F: Cohort 1D Cohort 1A and 1D JCAR017 Plus CC-99282 (Post-JCAR017 Infusion)
n=2 Participants
JCAR017 was administered at a dose of (100 x 10\^6 CAR+ T cells). Starting on Day 1 post infusion, CC-99282 was administered every 7 days. Participants received CC-99282 until Day 85 (Month 3)
|
Total
n=62 Participants
Total of all reporting groups
|
|---|---|---|---|---|---|---|---|---|---|
|
Age, Continuous
|
61.9 Years
STANDARD_DEVIATION 8.40 • n=5 Participants
|
68.6 Years
STANDARD_DEVIATION 6.65 • n=7 Participants
|
60.8 Years
STANDARD_DEVIATION 14.66 • n=5 Participants
|
69.0 Years
STANDARD_DEVIATION NA • n=4 Participants
|
56.5 Years
STANDARD_DEVIATION 12.19 • n=21 Participants
|
66.5 Years
STANDARD_DEVIATION 2.12 • n=10 Participants
|
66.6 Years
STANDARD_DEVIATION 14.14 • n=115 Participants
|
55.0 Years
STANDARD_DEVIATION 19.8 • n=6 Participants
|
61.7 Years
STANDARD_DEVIATION 11.92 • n=6 Participants
|
|
Sex: Female, Male
Female
|
3 Participants
n=5 Participants
|
3 Participants
n=7 Participants
|
1 Participants
n=5 Participants
|
0 Participants
n=4 Participants
|
7 Participants
n=21 Participants
|
0 Participants
n=10 Participants
|
4 Participants
n=115 Participants
|
1 Participants
n=6 Participants
|
19 Participants
n=6 Participants
|
|
Sex: Female, Male
Male
|
8 Participants
n=5 Participants
|
6 Participants
n=7 Participants
|
12 Participants
n=5 Participants
|
1 Participants
n=4 Participants
|
10 Participants
n=21 Participants
|
2 Participants
n=10 Participants
|
3 Participants
n=115 Participants
|
1 Participants
n=6 Participants
|
43 Participants
n=6 Participants
|
|
Ethnicity (NIH/OMB)
Hispanic or Latino
|
1 Participants
n=5 Participants
|
1 Participants
n=7 Participants
|
0 Participants
n=5 Participants
|
0 Participants
n=4 Participants
|
2 Participants
n=21 Participants
|
0 Participants
n=10 Participants
|
1 Participants
n=115 Participants
|
0 Participants
n=6 Participants
|
5 Participants
n=6 Participants
|
|
Ethnicity (NIH/OMB)
Not Hispanic or Latino
|
10 Participants
n=5 Participants
|
8 Participants
n=7 Participants
|
13 Participants
n=5 Participants
|
1 Participants
n=4 Participants
|
15 Participants
n=21 Participants
|
2 Participants
n=10 Participants
|
6 Participants
n=115 Participants
|
2 Participants
n=6 Participants
|
57 Participants
n=6 Participants
|
|
Ethnicity (NIH/OMB)
Unknown or Not Reported
|
0 Participants
n=5 Participants
|
0 Participants
n=7 Participants
|
0 Participants
n=5 Participants
|
0 Participants
n=4 Participants
|
0 Participants
n=21 Participants
|
0 Participants
n=10 Participants
|
0 Participants
n=115 Participants
|
0 Participants
n=6 Participants
|
0 Participants
n=6 Participants
|
|
Race/Ethnicity, Customized
AMERICAN INDIAN OR ALASKA NATIVE
|
0 Participants
n=5 Participants • Race
|
0 Participants
n=7 Participants • Race
|
0 Participants
n=5 Participants • Race
|
0 Participants
n=4 Participants • Race
|
1 Participants
n=21 Participants • Race
|
0 Participants
n=10 Participants • Race
|
0 Participants
n=115 Participants • Race
|
0 Participants
n=6 Participants • Race
|
1 Participants
n=6 Participants • Race
|
|
Race/Ethnicity, Customized
ASIAN
|
0 Participants
n=5 Participants • Race
|
0 Participants
n=7 Participants • Race
|
0 Participants
n=5 Participants • Race
|
0 Participants
n=4 Participants • Race
|
2 Participants
n=21 Participants • Race
|
0 Participants
n=10 Participants • Race
|
0 Participants
n=115 Participants • Race
|
1 Participants
n=6 Participants • Race
|
3 Participants
n=6 Participants • Race
|
|
Race/Ethnicity, Customized
BLACK OR AFRICAN AMERICAN
|
1 Participants
n=5 Participants • Race
|
0 Participants
n=7 Participants • Race
|
1 Participants
n=5 Participants • Race
|
0 Participants
n=4 Participants • Race
|
1 Participants
n=21 Participants • Race
|
0 Participants
n=10 Participants • Race
|
0 Participants
n=115 Participants • Race
|
0 Participants
n=6 Participants • Race
|
3 Participants
n=6 Participants • Race
|
|
Race/Ethnicity, Customized
WHITE
|
9 Participants
n=5 Participants • Race
|
9 Participants
n=7 Participants • Race
|
12 Participants
n=5 Participants • Race
|
1 Participants
n=4 Participants • Race
|
11 Participants
n=21 Participants • Race
|
2 Participants
n=10 Participants • Race
|
6 Participants
n=115 Participants • Race
|
1 Participants
n=6 Participants • Race
|
51 Participants
n=6 Participants • Race
|
|
Race/Ethnicity, Customized
OTHER
|
1 Participants
n=5 Participants • Race
|
0 Participants
n=7 Participants • Race
|
0 Participants
n=5 Participants • Race
|
0 Participants
n=4 Participants • Race
|
2 Participants
n=21 Participants • Race
|
0 Participants
n=10 Participants • Race
|
1 Participants
n=115 Participants • Race
|
0 Participants
n=6 Participants • Race
|
4 Participants
n=6 Participants • Race
|
PRIMARY outcome
Timeframe: From first dose of the combination agent until 1 month (28 days) after JCAR017 infusion (pre- JCAR017 cohort) or from JCAR017 infusion until 1 month (28 days) after the first dose of combination agent (post-JCAR017 cohort)Population: Dose-Limiting Toxicity Evaluable Participants. Prespecified to be reported per Arm and not per cohort.
Participants enrolled in Phase 1 are considered evaluable for DLTs if they received an infusion of conforming JCAR017 cell product and at least one dose of the combination agent and completed the specified DLT evaluation period or if they have received an infusion of conforming JCAR017 cell product and at least one dose of the combination agent and experience a DLT during the DLT evaluation period.
Outcome measures
| Measure |
Arm A: Cohort 1A and 1B JCAR017 Plus Durvalumab (Post-JCAR017 Infusion)
n=14 Participants
JCAR017 was administered at a dose of 50 x 10\^6 CAR+T cells (dose level 1 \[DL1\]) or 100 x 10\^6 CAR+T cells (DL2). On Day 29 after infusion, Durvalumab was administered at different doses and/ or schedules. Participants from both phases and all cohorts who reached a partial response 3 months after JCAR017 infusion could continue durvalumab until progression for a maximum total duration of 12 months.
|
Arm B: JCAR017 Plus CC-122 (Post-JCAR017 Infusion)
n=8 Participants
JCAR017 was administered at a dose of 100 x 10\^6 CAR+T cells (DL2). On Day 29 after infusion, CC-122 was administered at different doses. Participants who reach a partial response or stable disease 6 months (Day 180) after JCAR017 infusion could continue CC-122 until progression or for up to Month 24, whatever was earlier.
|
Arm C: JCAR017 Plus CC-220 (Iberdomide) (Post-JCAR017 Infusion)
n=1 Participants
JCAR017 was administered at a dose of 100 x 10\^6 CAR+T cells (DL2). Between Days 1 -21 post infusion, CC-220 was administered at different doses and/or schedules. Participants who reached a partial response or stable disease at Day 85 (Month 3) after JCAR017 infusion could continue CC-220 until progression or for up to Month 12, whichever was earlier.
|
Arm D: JCAR017 Plus Ibrutinib (Pre- and Post-JCAR017 Infusion)
n=8 Participants
Ibrutinib was administered at different doses on Day 1. On day 35, JCAR017 was administered at a dose of 100 x 10\^6 CAR+T cells (DL2), followed again by Ibrutinib at different doses. Participants received ibrutinib until 85 days post-infusion (Month 3).
|
Arm E: JCAR017 Plus Relatlimab and/or Nivolumab (Post-JCAR017 Infusion)
n=2 Participants
JCAR017 was administered at a dose of 100 x 10\^6 CAR+T cells (DL2). On day 8 or day 15 post infusion, relatlimab and nivolumab were administered at different doses and/or schedules. Participants received relatlimab and/or nivolumab until Day 85 (Month 3).
|
Arm F: Cohort 1A and 1D JCAR017 Plus CC-99282 (Post-JCAR017 Infusion)
n=5 Participants
JCAR017 was administered at a dose of 100 x 10\^6 CAR+T cells (DL2). On day 1, 8, or day 15 post infusion CC-99282 was administered at different doses and/or schedules. Participants received CC-99282 until Day 85 (Month 3).
|
|---|---|---|---|---|---|---|
|
Number of Participants With Dose-Limiting Toxicity (DLT)
|
0 Participants
|
2 Participants
|
1 Participants
|
1 Participants
|
0 Participants
|
0 Participants
|
PRIMARY outcome
Timeframe: At 3 and 6 months post-JCAR017 infusion.Population: All participants in the combination treated set. The combination treated set included all participants who received an infusion of conforming JCAR017 cell product and at least one dose of the combination agent. Prespecified to be reported per Arm and not per cohort.
Percentage of participants achieving a complete response (CR). CR is complete radiologic response (CRR) and complete metabolic response (CMR). CR was measured using CT and PET and assessed for the presence of index and non-index lesions, spleen size, and the absence of new lesions or diseased bone marrow. To be considered as having CRR participants had to have all of the following: * Index lesions - longest transverse diameter of nodal lesions ≤ 1.5 cm and the absence of extranodal disease. * Non-index lesions - the absence of non-index lesions. * Spleen size \<13 cm * The absence of new lesions * Normal bone marrow assessment To be considered as having CMR participants had to have all of the following: * A score of 1, 2, or 3 with or without residual mass on 5-PS for index and non-index lesions. * The absence of new lesions * No evidence of FDG-avid disease in marrow and a normal bone marrow assessment
Outcome measures
| Measure |
Arm A: Cohort 1A and 1B JCAR017 Plus Durvalumab (Post-JCAR017 Infusion)
n=14 Participants
JCAR017 was administered at a dose of 50 x 10\^6 CAR+T cells (dose level 1 \[DL1\]) or 100 x 10\^6 CAR+T cells (DL2). On Day 29 after infusion, Durvalumab was administered at different doses and/ or schedules. Participants from both phases and all cohorts who reached a partial response 3 months after JCAR017 infusion could continue durvalumab until progression for a maximum total duration of 12 months.
|
Arm B: JCAR017 Plus CC-122 (Post-JCAR017 Infusion)
n=8 Participants
JCAR017 was administered at a dose of 100 x 10\^6 CAR+T cells (DL2). On Day 29 after infusion, CC-122 was administered at different doses. Participants who reach a partial response or stable disease 6 months (Day 180) after JCAR017 infusion could continue CC-122 until progression or for up to Month 24, whatever was earlier.
|
Arm C: JCAR017 Plus CC-220 (Iberdomide) (Post-JCAR017 Infusion)
n=1 Participants
JCAR017 was administered at a dose of 100 x 10\^6 CAR+T cells (DL2). Between Days 1 -21 post infusion, CC-220 was administered at different doses and/or schedules. Participants who reached a partial response or stable disease at Day 85 (Month 3) after JCAR017 infusion could continue CC-220 until progression or for up to Month 12, whichever was earlier.
|
Arm D: JCAR017 Plus Ibrutinib (Pre- and Post-JCAR017 Infusion)
n=15 Participants
Ibrutinib was administered at different doses on Day 1. On day 35, JCAR017 was administered at a dose of 100 x 10\^6 CAR+T cells (DL2), followed again by Ibrutinib at different doses. Participants received ibrutinib until 85 days post-infusion (Month 3).
|
Arm E: JCAR017 Plus Relatlimab and/or Nivolumab (Post-JCAR017 Infusion)
n=2 Participants
JCAR017 was administered at a dose of 100 x 10\^6 CAR+T cells (DL2). On day 8 or day 15 post infusion, relatlimab and nivolumab were administered at different doses and/or schedules. Participants received relatlimab and/or nivolumab until Day 85 (Month 3).
|
Arm F: Cohort 1A and 1D JCAR017 Plus CC-99282 (Post-JCAR017 Infusion)
n=5 Participants
JCAR017 was administered at a dose of 100 x 10\^6 CAR+T cells (DL2). On day 1, 8, or day 15 post infusion CC-99282 was administered at different doses and/or schedules. Participants received CC-99282 until Day 85 (Month 3).
|
|---|---|---|---|---|---|---|
|
Complete Response Rate (CRR)
CRR at 3 Months
|
71.4 Percent of Participants
Interval 41.9 to 91.6
|
62.5 Percent of Participants
Interval 24.5 to 91.5
|
0.0 Percent of Participants
Interval 0.0 to 97.5
|
46.7 Percent of Participants
Interval 21.3 to 73.4
|
0.0 Percent of Participants
Interval 0.0 to 84.2
|
60.0 Percent of Participants
Interval 14.7 to 94.7
|
|
Complete Response Rate (CRR)
CRR at 6 Months
|
78.6 Percent of Participants
Interval 49.2 to 95.3
|
62.5 Percent of Participants
Interval 24.5 to 91.5
|
0.0 Percent of Participants
Interval 0.0 to 97.5
|
53.3 Percent of Participants
Interval 26.6 to 78.7
|
0.0 Percent of Participants
Interval 0.0 to 84.2
|
60.0 Percent of Participants
Interval 14.7 to 94.7
|
SECONDARY outcome
Timeframe: At baseline and 29 days and 57 days post JCAR017 dosePopulation: All participants in the combination treated set with baseline or on treatment HRQoL Scores. The combination treated set included all participants who received an infusion of conforming JCAR017 cell product and at least one dose of the combination agent. Data was not, nor will ever be collected for Arms C, D, E, and F since participants in these arms did not enter phase 2. Prespecified to be reported per Arm and not per cohort.
The EORTC QLQ-C30 is composed of five functional scales (physical, role, emotional, cognitive and social), three symptom scales (fatigue, nausea/vomiting, and pain), a global health status/health-related quality of life (HRQoL) scale, and six single items (dyspnea, insomnia, appetite loss, constipation, diarrhea, and financial difficulties). The questionnaire is scored on a 4-point Likert response scale: 1 = not at all, 2 = a little, 3 = quite a bit, and 4 = very much. The raw score is calculated as the average of the items that contribute to the scale. The final scores are calculated via linear transformation of raw scores and range from 0 to 100. For functional scales (physical, role, emotional, social, cognitive and global health) higher scores indicate better QoL. For symptom scales (fatigue, nausea and vomiting and pain) and single items (dyspnea, insomnia, appetite loss, constipation, diarrhea and financial difficulties) lower scores indicate fewer symptoms, i.e. better QoL.
Outcome measures
| Measure |
Arm A: Cohort 1A and 1B JCAR017 Plus Durvalumab (Post-JCAR017 Infusion)
n=14 Participants
JCAR017 was administered at a dose of 50 x 10\^6 CAR+T cells (dose level 1 \[DL1\]) or 100 x 10\^6 CAR+T cells (DL2). On Day 29 after infusion, Durvalumab was administered at different doses and/ or schedules. Participants from both phases and all cohorts who reached a partial response 3 months after JCAR017 infusion could continue durvalumab until progression for a maximum total duration of 12 months.
|
Arm B: JCAR017 Plus CC-122 (Post-JCAR017 Infusion)
n=7 Participants
JCAR017 was administered at a dose of 100 x 10\^6 CAR+T cells (DL2). On Day 29 after infusion, CC-122 was administered at different doses. Participants who reach a partial response or stable disease 6 months (Day 180) after JCAR017 infusion could continue CC-122 until progression or for up to Month 24, whatever was earlier.
|
Arm C: JCAR017 Plus CC-220 (Iberdomide) (Post-JCAR017 Infusion)
JCAR017 was administered at a dose of 100 x 10\^6 CAR+T cells (DL2). Between Days 1 -21 post infusion, CC-220 was administered at different doses and/or schedules. Participants who reached a partial response or stable disease at Day 85 (Month 3) after JCAR017 infusion could continue CC-220 until progression or for up to Month 12, whichever was earlier.
|
Arm D: JCAR017 Plus Ibrutinib (Pre- and Post-JCAR017 Infusion)
Ibrutinib was administered at different doses on Day 1. On day 35, JCAR017 was administered at a dose of 100 x 10\^6 CAR+T cells (DL2), followed again by Ibrutinib at different doses. Participants received ibrutinib until 85 days post-infusion (Month 3).
|
Arm E: JCAR017 Plus Relatlimab and/or Nivolumab (Post-JCAR017 Infusion)
JCAR017 was administered at a dose of 100 x 10\^6 CAR+T cells (DL2). On day 8 or day 15 post infusion, relatlimab and nivolumab were administered at different doses and/or schedules. Participants received relatlimab and/or nivolumab until Day 85 (Month 3).
|
Arm F: Cohort 1A and 1D JCAR017 Plus CC-99282 (Post-JCAR017 Infusion)
JCAR017 was administered at a dose of 100 x 10\^6 CAR+T cells (DL2). On day 1, 8, or day 15 post infusion CC-99282 was administered at different doses and/or schedules. Participants received CC-99282 until Day 85 (Month 3).
|
|---|---|---|---|---|---|---|
|
European Organisation for Research and Treatment of Cancer - Quality of Life C30 Questionnaire (EORTC QLQ-C30) Scores - Phase 2
Physical Functioning - JCAR017 Day 57
|
81.90 Score on a scale
Standard Deviation 22.710
|
87.62 Score on a scale
Standard Deviation 15.119
|
—
|
—
|
—
|
—
|
|
European Organisation for Research and Treatment of Cancer - Quality of Life C30 Questionnaire (EORTC QLQ-C30) Scores - Phase 2
Role Functioning - Baseline
|
68.06 Score on a scale
Standard Deviation 35.858
|
78.57 Score on a scale
Standard Deviation 28.406
|
—
|
—
|
—
|
—
|
|
European Organisation for Research and Treatment of Cancer - Quality of Life C30 Questionnaire (EORTC QLQ-C30) Scores - Phase 2
Role Functioning - JCAR017 Day 29
|
75.00 Score on a scale
Standard Deviation 30.487
|
88.10 Score on a scale
Standard Deviation 18.545
|
—
|
—
|
—
|
—
|
|
European Organisation for Research and Treatment of Cancer - Quality of Life C30 Questionnaire (EORTC QLQ-C30) Scores - Phase 2
Role Functioning - JCAR017 Day 57
|
77.38 Score on a scale
Standard Deviation 27.431
|
83.33 Score on a scale
Standard Deviation 25.459
|
—
|
—
|
—
|
—
|
|
European Organisation for Research and Treatment of Cancer - Quality of Life C30 Questionnaire (EORTC QLQ-C30) Scores - Phase 2
Emotional Functioning -JCAR017 Day 29
|
86.90 Score on a scale
Standard Deviation 16.894
|
91.67 Score on a scale
Standard Deviation 12.729
|
—
|
—
|
—
|
—
|
|
European Organisation for Research and Treatment of Cancer - Quality of Life C30 Questionnaire (EORTC QLQ-C30) Scores - Phase 2
Emotional Functioning - JCAR017 Day 57
|
85.71 Score on a scale
Standard Deviation 16.803
|
89.29 Score on a scale
Standard Deviation 10.446
|
—
|
—
|
—
|
—
|
|
European Organisation for Research and Treatment of Cancer - Quality of Life C30 Questionnaire (EORTC QLQ-C30) Scores - Phase 2
Cognitive Functioning - Baseline
|
81.94 Score on a scale
Standard Deviation 18.060
|
95.24 Score on a scale
Standard Deviation 8.133
|
—
|
—
|
—
|
—
|
|
European Organisation for Research and Treatment of Cancer - Quality of Life C30 Questionnaire (EORTC QLQ-C30) Scores - Phase 2
Cognitive Functioning - JCAR017 Day 29
|
88.10 Score on a scale
Standard Deviation 13.757
|
92.86 Score on a scale
Standard Deviation 13.113
|
—
|
—
|
—
|
—
|
|
European Organisation for Research and Treatment of Cancer - Quality of Life C30 Questionnaire (EORTC QLQ-C30) Scores - Phase 2
Cognitive Functioning - JCAR017 Day 57
|
94.05 Score on a scale
Standard Deviation 12.416
|
92.86 Score on a scale
Standard Deviation 13.113
|
—
|
—
|
—
|
—
|
|
European Organisation for Research and Treatment of Cancer - Quality of Life C30 Questionnaire (EORTC QLQ-C30) Scores - Phase 2
Social Functioning - Baseline
|
69.44 Score on a scale
Standard Deviation 36.121
|
76.19 Score on a scale
Standard Deviation 23.288
|
—
|
—
|
—
|
—
|
|
European Organisation for Research and Treatment of Cancer - Quality of Life C30 Questionnaire (EORTC QLQ-C30) Scores - Phase 2
Social Functioning - JCAR017 Day 29
|
69.05 Score on a scale
Standard Deviation 21.540
|
88.10 Score on a scale
Standard Deviation 15.853
|
—
|
—
|
—
|
—
|
|
European Organisation for Research and Treatment of Cancer - Quality of Life C30 Questionnaire (EORTC QLQ-C30) Scores - Phase 2
Social Functioning - JCAR017 Day 57
|
80.95 Score on a scale
Standard Deviation 20.524
|
85.71 Score on a scale
Standard Deviation 20.250
|
—
|
—
|
—
|
—
|
|
European Organisation for Research and Treatment of Cancer - Quality of Life C30 Questionnaire (EORTC QLQ-C30) Scores - Phase 2
Fatigue - Baseline
|
37.96 Score on a scale
Standard Deviation 30.506
|
14.29 Score on a scale
Standard Deviation 16.623
|
—
|
—
|
—
|
—
|
|
European Organisation for Research and Treatment of Cancer - Quality of Life C30 Questionnaire (EORTC QLQ-C30) Scores - Phase 2
Fatigue - JCAR017 Day 29
|
26.98 Score on a scale
Standard Deviation 18.853
|
23.81 Score on a scale
Standard Deviation 18.624
|
—
|
—
|
—
|
—
|
|
European Organisation for Research and Treatment of Cancer - Quality of Life C30 Questionnaire (EORTC QLQ-C30) Scores - Phase 2
Fatigue - JCAR017 Day 57
|
32.54 Score on a scale
Standard Deviation 19.715
|
22.22 Score on a scale
Standard Deviation 22.222
|
—
|
—
|
—
|
—
|
|
European Organisation for Research and Treatment of Cancer - Quality of Life C30 Questionnaire (EORTC QLQ-C30) Scores - Phase 2
Nausea and Vomiting - Baseline
|
11.11 Score on a scale
Standard Deviation 28.721
|
7.14 Score on a scale
Standard Deviation 13.113
|
—
|
—
|
—
|
—
|
|
European Organisation for Research and Treatment of Cancer - Quality of Life C30 Questionnaire (EORTC QLQ-C30) Scores - Phase 2
Nausea and Vomiting - JCAR017 Day 29
|
9.52 Score on a scale
Standard Deviation 15.627
|
7.14 Score on a scale
Standard Deviation 8.909
|
—
|
—
|
—
|
—
|
|
European Organisation for Research and Treatment of Cancer - Quality of Life C30 Questionnaire (EORTC QLQ-C30) Scores - Phase 2
Nausea and Vomiting - JCAR017 Day 57
|
9.52 Score on a scale
Standard Deviation 14.194
|
0.00 Score on a scale
Standard Deviation 0.00
|
—
|
—
|
—
|
—
|
|
European Organisation for Research and Treatment of Cancer - Quality of Life C30 Questionnaire (EORTC QLQ-C30) Scores - Phase 2
Pain - Baseline
|
34.72 Score on a scale
Standard Deviation 35.146
|
16.67 Score on a scale
Standard Deviation 19.245
|
—
|
—
|
—
|
—
|
|
European Organisation for Research and Treatment of Cancer - Quality of Life C30 Questionnaire (EORTC QLQ-C30) Scores - Phase 2
Pain - JCAR017 Day 29
|
20.24 Score on a scale
Standard Deviation 29.365
|
16.67 Score on a scale
Standard Deviation 19.245
|
—
|
—
|
—
|
—
|
|
European Organisation for Research and Treatment of Cancer - Quality of Life C30 Questionnaire (EORTC QLQ-C30) Scores - Phase 2
Pain - JCAR017 Day 57
|
22.62 Score on a scale
Standard Deviation 30.387
|
14.29 Score on a scale
Standard Deviation 20.250
|
—
|
—
|
—
|
—
|
|
European Organisation for Research and Treatment of Cancer - Quality of Life C30 Questionnaire (EORTC QLQ-C30) Scores - Phase 2
Dyspnea - Baseline
|
16.67 Score on a scale
Standard Deviation 17.408
|
4.76 Score on a scale
Standard Deviation 12.599
|
—
|
—
|
—
|
—
|
|
European Organisation for Research and Treatment of Cancer - Quality of Life C30 Questionnaire (EORTC QLQ-C30) Scores - Phase 2
Dyspnea - JCAR017 Day 29
|
21.43 Score on a scale
Standard Deviation 21.111
|
4.76 Score on a scale
Standard Deviation 12.599
|
—
|
—
|
—
|
—
|
|
European Organisation for Research and Treatment of Cancer - Quality of Life C30 Questionnaire (EORTC QLQ-C30) Scores - Phase 2
Dyspnea - JCAR017 Day 57
|
14.29 Score on a scale
Standard Deviation 17.118
|
4.76 Score on a scale
Standard Deviation 12.599
|
—
|
—
|
—
|
—
|
|
European Organisation for Research and Treatment of Cancer - Quality of Life C30 Questionnaire (EORTC QLQ-C30) Scores - Phase 2
Insomnia - Baseline
|
41.67 Score on a scale
Standard Deviation 35.176
|
23.81 Score on a scale
Standard Deviation 25.198
|
—
|
—
|
—
|
—
|
|
European Organisation for Research and Treatment of Cancer - Quality of Life C30 Questionnaire (EORTC QLQ-C30) Scores - Phase 2
Insomnia - JCAR017 Day 29
|
16.67 Score on a scale
Standard Deviation 28.495
|
19.05 Score on a scale
Standard Deviation 14.29
|
—
|
—
|
—
|
—
|
|
European Organisation for Research and Treatment of Cancer - Quality of Life C30 Questionnaire (EORTC QLQ-C30) Scores - Phase 2
Appetite Loss - Baseline
|
25.00 Score on a scale
Standard Deviation 32.177
|
14.29 Score on a scale
Standard Deviation 17.817
|
—
|
—
|
—
|
—
|
|
European Organisation for Research and Treatment of Cancer - Quality of Life C30 Questionnaire (EORTC QLQ-C30) Scores - Phase 2
Appetite Loss - JCAR017 Day 29
|
26.19 Score on a scale
Standard Deviation 26.726
|
9.52 Score on a scale
Standard Deviation 16.265
|
—
|
—
|
—
|
—
|
|
European Organisation for Research and Treatment of Cancer - Quality of Life C30 Questionnaire (EORTC QLQ-C30) Scores - Phase 2
Appetite Loss - JCAR017 Day 57
|
21.43 Score on a scale
Standard Deviation 28.063
|
4.76 Score on a scale
Standard Deviation 12.599
|
—
|
—
|
—
|
—
|
|
European Organisation for Research and Treatment of Cancer - Quality of Life C30 Questionnaire (EORTC QLQ-C30) Scores - Phase 2
Constipation - Baseline
|
13.89 Score on a scale
Standard Deviation 30.011
|
4.76 Score on a scale
Standard Deviation 12.599
|
—
|
—
|
—
|
—
|
|
European Organisation for Research and Treatment of Cancer - Quality of Life C30 Questionnaire (EORTC QLQ-C30) Scores - Phase 2
Constipation - JCAR017 Day 29
|
11.90 Score on a scale
Standard Deviation 28.063
|
4.76 Score on a scale
Standard Deviation 12.599
|
—
|
—
|
—
|
—
|
|
European Organisation for Research and Treatment of Cancer - Quality of Life C30 Questionnaire (EORTC QLQ-C30) Scores - Phase 2
Constipation - JCAR017 Day 57
|
14.29 Score on a scale
Standard Deviation 17.118
|
0.00 Score on a scale
Standard Deviation 0.000
|
—
|
—
|
—
|
—
|
|
European Organisation for Research and Treatment of Cancer - Quality of Life C30 Questionnaire (EORTC QLQ-C30) Scores - Phase 2
Diarrhea - Baseline
|
5.56 Score on a scale
Standard Deviation 12.975
|
9.52 Score on a scale
Standard Deviation 16.265
|
—
|
—
|
—
|
—
|
|
European Organisation for Research and Treatment of Cancer - Quality of Life C30 Questionnaire (EORTC QLQ-C30) Scores - Phase 2
Diarrhea - JCAR017 Day 29
|
7.14 Score on a scale
Standard Deviation 14.194
|
4.76 Score on a scale
Standard Deviation 12.599
|
—
|
—
|
—
|
—
|
|
European Organisation for Research and Treatment of Cancer - Quality of Life C30 Questionnaire (EORTC QLQ-C30) Scores - Phase 2
Diarrhea - JCAR017 Day 57
|
0.00 Score on a scale
Standard Deviation 0.000
|
9.52 Score on a scale
Standard Deviation 16.265
|
—
|
—
|
—
|
—
|
|
European Organisation for Research and Treatment of Cancer - Quality of Life C30 Questionnaire (EORTC QLQ-C30) Scores - Phase 2
Financial Difficulties - Baseline
|
30.56 Score on a scale
Standard Deviation 36.121
|
28.57 Score on a scale
Standard Deviation 29.991
|
—
|
—
|
—
|
—
|
|
European Organisation for Research and Treatment of Cancer - Quality of Life C30 Questionnaire (EORTC QLQ-C30) Scores - Phase 2
Financial Difficulties - JCAR017 Day 29
|
19.05 Score on a scale
Standard Deviation 31.254
|
23.81 Score on a scale
Standard Deviation 31.706
|
—
|
—
|
—
|
—
|
|
European Organisation for Research and Treatment of Cancer - Quality of Life C30 Questionnaire (EORTC QLQ-C30) Scores - Phase 2
Emotional Functioning - Baseline
|
77.08 Score on a scale
Standard Deviation 21.059
|
85.71 Score on a scale
Standard Deviation 12.467
|
—
|
—
|
—
|
—
|
|
European Organisation for Research and Treatment of Cancer - Quality of Life C30 Questionnaire (EORTC QLQ-C30) Scores - Phase 2
Insomnia - JCAR017 Day 57
|
35.71 Score on a scale
Standard Deviation 33.242
|
19.05 Score on a scale
Standard Deviation 17.817
|
—
|
—
|
—
|
—
|
|
European Organisation for Research and Treatment of Cancer - Quality of Life C30 Questionnaire (EORTC QLQ-C30) Scores - Phase 2
Global Health Status - Baseline
|
72.92 Score on a scale
Standard Deviation 20.140
|
80.95 Score on a scale
Standard Deviation 16.467
|
—
|
—
|
—
|
—
|
|
European Organisation for Research and Treatment of Cancer - Quality of Life C30 Questionnaire (EORTC QLQ-C30) Scores - Phase 2
Global Health Status - JCAR017 Day 29
|
70.24 Score on a scale
Standard Deviation 12.957
|
85.71 Score on a scale
Standard Deviation 20.813
|
—
|
—
|
—
|
—
|
|
European Organisation for Research and Treatment of Cancer - Quality of Life C30 Questionnaire (EORTC QLQ-C30) Scores - Phase 2
Global Health Status - JCAR017 Day 57
|
75.60 Score on a scale
Standard Deviation 13.660
|
89.29 Score on a scale
Standard Deviation 12.467
|
—
|
—
|
—
|
—
|
|
European Organisation for Research and Treatment of Cancer - Quality of Life C30 Questionnaire (EORTC QLQ-C30) Scores - Phase 2
Physical Functioning - Baseline
|
80.00 Score on a scale
Standard Deviation 23.613
|
86.67 Score on a scale
Standard Deviation 13.333
|
—
|
—
|
—
|
—
|
|
European Organisation for Research and Treatment of Cancer - Quality of Life C30 Questionnaire (EORTC QLQ-C30) Scores - Phase 2
Physical Functioning - JCAR017 Day 29
|
80.48 Score on a scale
Standard Deviation 22.716
|
91.43 Score on a scale
Standard Deviation 10.690
|
—
|
—
|
—
|
—
|
|
European Organisation for Research and Treatment of Cancer - Quality of Life C30 Questionnaire (EORTC QLQ-C30) Scores - Phase 2
Financial Difficulties - JCAR017 Day 57
|
21.43 Score on a scale
Standard Deviation 30.959
|
28.57 Score on a scale
Standard Deviation 29.991
|
—
|
—
|
—
|
—
|
SECONDARY outcome
Timeframe: At baseline and 1, 29, 57, 85, 180, 270, 365, 545, and 730 days post JCAR017 dosePopulation: All participants in the combination treated set with baseline or on treatment HRQoL Scores. The combination treated set included all participants who received an infusion of conforming JCAR017 cell product and at least one dose of the combination agent. Data was not, nor will ever be collected for Arms C, D, E, and F as participants in these Arms did not enter phase 2. Prespecified to be reported per Arm and not per cohort.
The EuroQol- 5 Dimensions of Health Visual Analogue Scale (EQ-5D VAS) records the participant's self-rated health on a vertical visual analogue scale, where the endpoints are scored from 0 to 100 i.e., 'The worst health you can imagine' (score of 0) to 'The best health you can imagine' (score of 100). Higher scores indicate better health outcomes.
Outcome measures
| Measure |
Arm A: Cohort 1A and 1B JCAR017 Plus Durvalumab (Post-JCAR017 Infusion)
n=14 Participants
JCAR017 was administered at a dose of 50 x 10\^6 CAR+T cells (dose level 1 \[DL1\]) or 100 x 10\^6 CAR+T cells (DL2). On Day 29 after infusion, Durvalumab was administered at different doses and/ or schedules. Participants from both phases and all cohorts who reached a partial response 3 months after JCAR017 infusion could continue durvalumab until progression for a maximum total duration of 12 months.
|
Arm B: JCAR017 Plus CC-122 (Post-JCAR017 Infusion)
n=7 Participants
JCAR017 was administered at a dose of 100 x 10\^6 CAR+T cells (DL2). On Day 29 after infusion, CC-122 was administered at different doses. Participants who reach a partial response or stable disease 6 months (Day 180) after JCAR017 infusion could continue CC-122 until progression or for up to Month 24, whatever was earlier.
|
Arm C: JCAR017 Plus CC-220 (Iberdomide) (Post-JCAR017 Infusion)
JCAR017 was administered at a dose of 100 x 10\^6 CAR+T cells (DL2). Between Days 1 -21 post infusion, CC-220 was administered at different doses and/or schedules. Participants who reached a partial response or stable disease at Day 85 (Month 3) after JCAR017 infusion could continue CC-220 until progression or for up to Month 12, whichever was earlier.
|
Arm D: JCAR017 Plus Ibrutinib (Pre- and Post-JCAR017 Infusion)
Ibrutinib was administered at different doses on Day 1. On day 35, JCAR017 was administered at a dose of 100 x 10\^6 CAR+T cells (DL2), followed again by Ibrutinib at different doses. Participants received ibrutinib until 85 days post-infusion (Month 3).
|
Arm E: JCAR017 Plus Relatlimab and/or Nivolumab (Post-JCAR017 Infusion)
JCAR017 was administered at a dose of 100 x 10\^6 CAR+T cells (DL2). On day 8 or day 15 post infusion, relatlimab and nivolumab were administered at different doses and/or schedules. Participants received relatlimab and/or nivolumab until Day 85 (Month 3).
|
Arm F: Cohort 1A and 1D JCAR017 Plus CC-99282 (Post-JCAR017 Infusion)
JCAR017 was administered at a dose of 100 x 10\^6 CAR+T cells (DL2). On day 1, 8, or day 15 post infusion CC-99282 was administered at different doses and/or schedules. Participants received CC-99282 until Day 85 (Month 3).
|
|---|---|---|---|---|---|---|
|
EuroQol- 5 Dimensions of Health Visual Analogue Scale (EQ-5D VAS) Scores - Phase 2
Baseline
|
69.5 Score on a Scale
Standard Deviation 21.83
|
82.6 Score on a Scale
Standard Deviation 12.31
|
—
|
—
|
—
|
—
|
|
EuroQol- 5 Dimensions of Health Visual Analogue Scale (EQ-5D VAS) Scores - Phase 2
JCAR017 Day 1
|
75.1 Score on a Scale
Standard Deviation 13.62
|
89.1 Score on a Scale
Standard Deviation 12.13
|
—
|
—
|
—
|
—
|
|
EuroQol- 5 Dimensions of Health Visual Analogue Scale (EQ-5D VAS) Scores - Phase 2
JCAR017 Day 29
|
77.5 Score on a Scale
Standard Deviation 18.93
|
90.9 Score on a Scale
Standard Deviation 10.33
|
—
|
—
|
—
|
—
|
|
EuroQol- 5 Dimensions of Health Visual Analogue Scale (EQ-5D VAS) Scores - Phase 2
JCAR017 Day 57
|
81.2 Score on a Scale
Standard Deviation 16.20
|
90.3 Score on a Scale
Standard Deviation 9.43
|
—
|
—
|
—
|
—
|
|
EuroQol- 5 Dimensions of Health Visual Analogue Scale (EQ-5D VAS) Scores - Phase 2
JCAR017 Day 85
|
88.4 Score on a Scale
Standard Deviation 8.47
|
93.0 Score on a Scale
Standard Deviation 4.98
|
—
|
—
|
—
|
—
|
|
EuroQol- 5 Dimensions of Health Visual Analogue Scale (EQ-5D VAS) Scores - Phase 2
JCAR017 Day 180
|
86.0 Score on a Scale
Standard Deviation 10.68
|
90.8 Score on a Scale
Standard Deviation 13.96
|
—
|
—
|
—
|
—
|
|
EuroQol- 5 Dimensions of Health Visual Analogue Scale (EQ-5D VAS) Scores - Phase 2
Follow-up - Day 270
|
88.7 Score on a Scale
Standard Deviation 7.50
|
96.0 Score on a Scale
Standard Deviation 1.41
|
—
|
—
|
—
|
—
|
|
EuroQol- 5 Dimensions of Health Visual Analogue Scale (EQ-5D VAS) Scores - Phase 2
Follow-up - Day 365
|
89.2 Score on a Scale
Standard Deviation 15.22
|
98.0 Score on a Scale
Standard Deviation 2.83
|
—
|
—
|
—
|
—
|
|
EuroQol- 5 Dimensions of Health Visual Analogue Scale (EQ-5D VAS) Scores - Phase 2
Follow-up - Day 545
|
89.7 Score on a Scale
Standard Deviation 0.58
|
95.0 Score on a Scale
Standard Deviation NA
Insufficient number of participants to calculate SD.
|
—
|
—
|
—
|
—
|
|
EuroQol- 5 Dimensions of Health Visual Analogue Scale (EQ-5D VAS) Scores - Phase 2
Follow-up - Day 730/EOS
|
79.3 Score on a Scale
Standard Deviation 15.84
|
96.3 Score on a Scale
Standard Deviation 3.21
|
—
|
—
|
—
|
—
|
SECONDARY outcome
Timeframe: Up to 3 months after the dose of JCAR017 or after the last dose of the combination agent, whichever occurred last (an average of 6.5 months up until a max of 9.5 months)Population: Safety Set - All participants who received an infusion of conforming JCAR017 cell product or at least one dose of the combination agent. Prespecified to be reported per Arm and not per cohort.
An AE is any noxious, unintended, or untoward medical occurrence that may appear or worsen in a participant during the course of a study. It may be a new intercurrent illness, a worsening concomitant illness, an injury, or any concomitant impairment of the participant's health, including laboratory test values, regardless of etiology. Any worsening (i.e., any clinically significant adverse change in the frequency or intensity of a preexisting condition) is also considered an AE. All participants were monitored for AEs during the study. Assessments included monitoring of any or all of the following parameters: the participant's clinical symptoms, laboratory, pathological, radiological or surgical findings, physical examination findings, or findings from other tests and/or procedures.
Outcome measures
| Measure |
Arm A: Cohort 1A and 1B JCAR017 Plus Durvalumab (Post-JCAR017 Infusion)
n=16 Participants
JCAR017 was administered at a dose of 50 x 10\^6 CAR+T cells (dose level 1 \[DL1\]) or 100 x 10\^6 CAR+T cells (DL2). On Day 29 after infusion, Durvalumab was administered at different doses and/ or schedules. Participants from both phases and all cohorts who reached a partial response 3 months after JCAR017 infusion could continue durvalumab until progression for a maximum total duration of 12 months.
|
Arm B: JCAR017 Plus CC-122 (Post-JCAR017 Infusion)
n=11 Participants
JCAR017 was administered at a dose of 100 x 10\^6 CAR+T cells (DL2). On Day 29 after infusion, CC-122 was administered at different doses. Participants who reach a partial response or stable disease 6 months (Day 180) after JCAR017 infusion could continue CC-122 until progression or for up to Month 24, whatever was earlier.
|
Arm C: JCAR017 Plus CC-220 (Iberdomide) (Post-JCAR017 Infusion)
n=1 Participants
JCAR017 was administered at a dose of 100 x 10\^6 CAR+T cells (DL2). Between Days 1 -21 post infusion, CC-220 was administered at different doses and/or schedules. Participants who reached a partial response or stable disease at Day 85 (Month 3) after JCAR017 infusion could continue CC-220 until progression or for up to Month 12, whichever was earlier.
|
Arm D: JCAR017 Plus Ibrutinib (Pre- and Post-JCAR017 Infusion)
n=17 Participants
Ibrutinib was administered at different doses on Day 1. On day 35, JCAR017 was administered at a dose of 100 x 10\^6 CAR+T cells (DL2), followed again by Ibrutinib at different doses. Participants received ibrutinib until 85 days post-infusion (Month 3).
|
Arm E: JCAR017 Plus Relatlimab and/or Nivolumab (Post-JCAR017 Infusion)
n=2 Participants
JCAR017 was administered at a dose of 100 x 10\^6 CAR+T cells (DL2). On day 8 or day 15 post infusion, relatlimab and nivolumab were administered at different doses and/or schedules. Participants received relatlimab and/or nivolumab until Day 85 (Month 3).
|
Arm F: Cohort 1A and 1D JCAR017 Plus CC-99282 (Post-JCAR017 Infusion)
n=6 Participants
JCAR017 was administered at a dose of 100 x 10\^6 CAR+T cells (DL2). On day 1, 8, or day 15 post infusion CC-99282 was administered at different doses and/or schedules. Participants received CC-99282 until Day 85 (Month 3).
|
|---|---|---|---|---|---|---|
|
Number of Participants With Adverse Events (AEs)
|
16 Participants
|
11 Participants
|
1 Participants
|
17 Participants
|
2 Participants
|
6 Participants
|
SECONDARY outcome
Timeframe: Up to 3 months after the dose of JCAR017 or after the last dose of the combination agent, whichever occurred last (an average of 6.5 months up until a max of 9.5 months)Population: Safety Set - All participants who received an infusion of conforming JCAR017 cell product or at least one dose of the combination agent. Prespecified to be reported per Arm and not per cohort.
An SAE is any AE occurring at any dose that: * Results in death; * Is life-threatening (i.e., in the opinion of the Investigator, the participant is at immediate risk of death from the AE); * Requires inpatient hospitalization or prolongation of existing hospitalization (hospitalization is defined as an inpatient admission, regardless of length of stay); * Results in persistent or significant disability/incapacity (a substantial disruption of the participant's ability to conduct normal life functions); * Is a congenital anomaly/birth defect; * Constitutes an important medical event.
Outcome measures
| Measure |
Arm A: Cohort 1A and 1B JCAR017 Plus Durvalumab (Post-JCAR017 Infusion)
n=16 Participants
JCAR017 was administered at a dose of 50 x 10\^6 CAR+T cells (dose level 1 \[DL1\]) or 100 x 10\^6 CAR+T cells (DL2). On Day 29 after infusion, Durvalumab was administered at different doses and/ or schedules. Participants from both phases and all cohorts who reached a partial response 3 months after JCAR017 infusion could continue durvalumab until progression for a maximum total duration of 12 months.
|
Arm B: JCAR017 Plus CC-122 (Post-JCAR017 Infusion)
n=11 Participants
JCAR017 was administered at a dose of 100 x 10\^6 CAR+T cells (DL2). On Day 29 after infusion, CC-122 was administered at different doses. Participants who reach a partial response or stable disease 6 months (Day 180) after JCAR017 infusion could continue CC-122 until progression or for up to Month 24, whatever was earlier.
|
Arm C: JCAR017 Plus CC-220 (Iberdomide) (Post-JCAR017 Infusion)
n=1 Participants
JCAR017 was administered at a dose of 100 x 10\^6 CAR+T cells (DL2). Between Days 1 -21 post infusion, CC-220 was administered at different doses and/or schedules. Participants who reached a partial response or stable disease at Day 85 (Month 3) after JCAR017 infusion could continue CC-220 until progression or for up to Month 12, whichever was earlier.
|
Arm D: JCAR017 Plus Ibrutinib (Pre- and Post-JCAR017 Infusion)
n=17 Participants
Ibrutinib was administered at different doses on Day 1. On day 35, JCAR017 was administered at a dose of 100 x 10\^6 CAR+T cells (DL2), followed again by Ibrutinib at different doses. Participants received ibrutinib until 85 days post-infusion (Month 3).
|
Arm E: JCAR017 Plus Relatlimab and/or Nivolumab (Post-JCAR017 Infusion)
n=2 Participants
JCAR017 was administered at a dose of 100 x 10\^6 CAR+T cells (DL2). On day 8 or day 15 post infusion, relatlimab and nivolumab were administered at different doses and/or schedules. Participants received relatlimab and/or nivolumab until Day 85 (Month 3).
|
Arm F: Cohort 1A and 1D JCAR017 Plus CC-99282 (Post-JCAR017 Infusion)
n=6 Participants
JCAR017 was administered at a dose of 100 x 10\^6 CAR+T cells (DL2). On day 1, 8, or day 15 post infusion CC-99282 was administered at different doses and/or schedules. Participants received CC-99282 until Day 85 (Month 3).
|
|---|---|---|---|---|---|---|
|
Number of Participants With Severe Adverse Events (SAEs)
|
10 Participants
|
7 Participants
|
1 Participants
|
6 Participants
|
2 Participants
|
3 Participants
|
SECONDARY outcome
Timeframe: 85 days after the dose of JCAR017 for Arms A, B, D, E, and F; 57 days after the dose of JCAR017 for Arm CPopulation: All treated participants with baseline and Day 85/Day 57 hematology laboratory values. Prespecified to be reported per Arm and not per cohort.
White blood cell, and platelet counts. Baseline is defined as the last measurement on or prior to any study treatment.
Outcome measures
| Measure |
Arm A: Cohort 1A and 1B JCAR017 Plus Durvalumab (Post-JCAR017 Infusion)
n=11 Participants
JCAR017 was administered at a dose of 50 x 10\^6 CAR+T cells (dose level 1 \[DL1\]) or 100 x 10\^6 CAR+T cells (DL2). On Day 29 after infusion, Durvalumab was administered at different doses and/ or schedules. Participants from both phases and all cohorts who reached a partial response 3 months after JCAR017 infusion could continue durvalumab until progression for a maximum total duration of 12 months.
|
Arm B: JCAR017 Plus CC-122 (Post-JCAR017 Infusion)
n=7 Participants
JCAR017 was administered at a dose of 100 x 10\^6 CAR+T cells (DL2). On Day 29 after infusion, CC-122 was administered at different doses. Participants who reach a partial response or stable disease 6 months (Day 180) after JCAR017 infusion could continue CC-122 until progression or for up to Month 24, whatever was earlier.
|
Arm C: JCAR017 Plus CC-220 (Iberdomide) (Post-JCAR017 Infusion)
n=1 Participants
JCAR017 was administered at a dose of 100 x 10\^6 CAR+T cells (DL2). Between Days 1 -21 post infusion, CC-220 was administered at different doses and/or schedules. Participants who reached a partial response or stable disease at Day 85 (Month 3) after JCAR017 infusion could continue CC-220 until progression or for up to Month 12, whichever was earlier.
|
Arm D: JCAR017 Plus Ibrutinib (Pre- and Post-JCAR017 Infusion)
n=12 Participants
Ibrutinib was administered at different doses on Day 1. On day 35, JCAR017 was administered at a dose of 100 x 10\^6 CAR+T cells (DL2), followed again by Ibrutinib at different doses. Participants received ibrutinib until 85 days post-infusion (Month 3).
|
Arm E: JCAR017 Plus Relatlimab and/or Nivolumab (Post-JCAR017 Infusion)
n=2 Participants
JCAR017 was administered at a dose of 100 x 10\^6 CAR+T cells (DL2). On day 8 or day 15 post infusion, relatlimab and nivolumab were administered at different doses and/or schedules. Participants received relatlimab and/or nivolumab until Day 85 (Month 3).
|
Arm F: Cohort 1A and 1D JCAR017 Plus CC-99282 (Post-JCAR017 Infusion)
n=4 Participants
JCAR017 was administered at a dose of 100 x 10\^6 CAR+T cells (DL2). On day 1, 8, or day 15 post infusion CC-99282 was administered at different doses and/or schedules. Participants received CC-99282 until Day 85 (Month 3).
|
|---|---|---|---|---|---|---|
|
Change From Baseline in White Blood Cell and Platelet Numbers
BASOPHILS (10^9/L)
|
0.00 10^9 cells/L
Standard Deviation 0.009
|
0.03 10^9 cells/L
Standard Deviation 0.050
|
0.10 10^9 cells/L
Standard Deviation NA
Insufficient number of participants to calculate SD
|
-0.02 10^9 cells/L
Standard Deviation 0.038
|
0.05 10^9 cells/L
Standard Deviation 0.071
|
0.00 10^9 cells/L
Standard Deviation 0.075
|
|
Change From Baseline in White Blood Cell and Platelet Numbers
EOSINOPHILS (10^9/L)
|
0.20 10^9 cells/L
Standard Deviation 0.134
|
0.20 10^9 cells/L
Standard Deviation 0.282
|
0.00 10^9 cells/L
Standard Deviation NA
Insufficient number of participants to calculate SD
|
0.01 10^9 cells/L
Standard Deviation 0.062
|
-0.05 10^9 cells/L
Standard Deviation 0.071
|
0.04 10^9 cells/L
Standard Deviation 0.057
|
|
Change From Baseline in White Blood Cell and Platelet Numbers
LYMPHOCYTES (10^9/L)
|
0.40 10^9 cells/L
Standard Deviation 0.359
|
0.29 10^9 cells/L
Standard Deviation 0.138
|
-0.60 10^9 cells/L
Standard Deviation NA
Insufficient number of participants to calculate SD
|
-0.20 10^9 cells/L
Standard Deviation 0.828
|
1.00 10^9 cells/L
Standard Deviation 0.707
|
0.87 10^9 cells/L
Standard Deviation 0.757
|
|
Change From Baseline in White Blood Cell and Platelet Numbers
MONOCYTES (10^9/L)
|
0.19 10^9 cells/L
Standard Deviation 0.209
|
0.38 10^9 cells/L
Standard Deviation 0.295
|
0.20 10^9 cells/L
Standard Deviation NA
Insufficient number of participants to calculate SD
|
-0.27 10^9 cells/L
Standard Deviation 0.527
|
0.15 10^9 cells/L
Standard Deviation 0.212
|
0.21 10^9 cells/L
Standard Deviation 0.279
|
|
Change From Baseline in White Blood Cell and Platelet Numbers
NEUTROPHILS (10^9/L)
|
-1.69 10^9 cells/L
Standard Deviation 1.940
|
-1.74 10^9 cells/L
Standard Deviation 1.312
|
2.30 10^9 cells/L
Standard Deviation NA
Insufficient number of participants to calculate SD
|
-4.98 10^9 cells/L
Standard Deviation 8.198
|
1.95 10^9 cells/L
Standard Deviation 3.889
|
-2.47 10^9 cells/L
Standard Deviation 3.335
|
|
Change From Baseline in White Blood Cell and Platelet Numbers
PLATELETS (10^9/L)
|
-6.91 10^9 cells/L
Standard Deviation 59.184
|
25.57 10^9 cells/L
Standard Deviation 28.547
|
-77.00 10^9 cells/L
Standard Deviation NA
Insufficient number of participants to calculate SD
|
-125.92 10^9 cells/L
Standard Deviation 107.421
|
-0.50 10^9 cells/L
Standard Deviation 20.506
|
-11.00 10^9 cells/L
Standard Deviation 111.146
|
SECONDARY outcome
Timeframe: 85 days after the dose of JCAR017 for Arms A, B, D, E, and F; 57 days after the dose of JCAR017 for Arm CPopulation: All treated participants with baseline and Day 85/Day 57 hematology laboratory values. Prespecified to be reported per Arm and not per cohort.
Change from baseline in percent of white blood cells was measured using differential blood tests. A differential blood test is a blood test that measures the percentage and number of each type of white blood cell (WBC) - neutrophils, lymphocytes, monocytes, eosinophils and basophils - as well as abnormal cell types if they are present. These results are reported as percentages and absolute values, and compared against reference ranges to determine whether the values are normal, low, or high. Baseline is defined as the last measurement on or prior to any study treatment.
Outcome measures
| Measure |
Arm A: Cohort 1A and 1B JCAR017 Plus Durvalumab (Post-JCAR017 Infusion)
n=11 Participants
JCAR017 was administered at a dose of 50 x 10\^6 CAR+T cells (dose level 1 \[DL1\]) or 100 x 10\^6 CAR+T cells (DL2). On Day 29 after infusion, Durvalumab was administered at different doses and/ or schedules. Participants from both phases and all cohorts who reached a partial response 3 months after JCAR017 infusion could continue durvalumab until progression for a maximum total duration of 12 months.
|
Arm B: JCAR017 Plus CC-122 (Post-JCAR017 Infusion)
n=7 Participants
JCAR017 was administered at a dose of 100 x 10\^6 CAR+T cells (DL2). On Day 29 after infusion, CC-122 was administered at different doses. Participants who reach a partial response or stable disease 6 months (Day 180) after JCAR017 infusion could continue CC-122 until progression or for up to Month 24, whatever was earlier.
|
Arm C: JCAR017 Plus CC-220 (Iberdomide) (Post-JCAR017 Infusion)
n=1 Participants
JCAR017 was administered at a dose of 100 x 10\^6 CAR+T cells (DL2). Between Days 1 -21 post infusion, CC-220 was administered at different doses and/or schedules. Participants who reached a partial response or stable disease at Day 85 (Month 3) after JCAR017 infusion could continue CC-220 until progression or for up to Month 12, whichever was earlier.
|
Arm D: JCAR017 Plus Ibrutinib (Pre- and Post-JCAR017 Infusion)
n=12 Participants
Ibrutinib was administered at different doses on Day 1. On day 35, JCAR017 was administered at a dose of 100 x 10\^6 CAR+T cells (DL2), followed again by Ibrutinib at different doses. Participants received ibrutinib until 85 days post-infusion (Month 3).
|
Arm E: JCAR017 Plus Relatlimab and/or Nivolumab (Post-JCAR017 Infusion)
n=2 Participants
JCAR017 was administered at a dose of 100 x 10\^6 CAR+T cells (DL2). On day 8 or day 15 post infusion, relatlimab and nivolumab were administered at different doses and/or schedules. Participants received relatlimab and/or nivolumab until Day 85 (Month 3).
|
Arm F: Cohort 1A and 1D JCAR017 Plus CC-99282 (Post-JCAR017 Infusion)
n=4 Participants
JCAR017 was administered at a dose of 100 x 10\^6 CAR+T cells (DL2). On day 1, 8, or day 15 post infusion CC-99282 was administered at different doses and/or schedules. Participants received CC-99282 until Day 85 (Month 3).
|
|---|---|---|---|---|---|---|
|
Change From Baseline in Percent of White Blood Cells
BASOPHILS/LEUKOCYTES (%)
|
0.40 Percent
Standard Deviation 0.420
|
0.89 Percent
Standard Deviation 1.002
|
0.00 Percent
Standard Deviation NA
Insufficient number of participants to calculate SD
|
0.20 Percent
Standard Deviation 0.558
|
0.15 Percent
Standard Deviation 0.778
|
0.88 Percent
Standard Deviation 1.450
|
|
Change From Baseline in Percent of White Blood Cells
EOSINOPHILS/LEUKOCYTES (%)
|
1.24 Percent
Standard Deviation 2.455
|
5.20 Percent
Standard Deviation 6.491
|
-1.00 Percent
Standard Deviation NA
Insufficient number of participants to calculate SD
|
1.02 Percent
Standard Deviation 1.565
|
-0.40 Percent
Standard Deviation 0.283
|
1.45 Percent
Standard Deviation 3.264
|
|
Change From Baseline in Percent of White Blood Cells
LYMPHOCYTES/LEUKOCYTES (%)
|
11.59 Percent
Standard Deviation 7.902
|
9.29 Percent
Standard Deviation 4.870
|
-37.00 Percent
Standard Deviation NA
Insufficient number of participants to calculate SD
|
2.60 Percent
Standard Deviation 20.07
|
8.65 Percent
Standard Deviation 1.202
|
24.73 Percent
Standard Deviation 12.156
|
|
Change From Baseline in Percent of White Blood Cells
MONOCYTES/LEUKOCYTES (%)
|
7.13 Percent
Standard Deviation 3.955
|
11.43 Percent
Standard Deviation 6.574
|
-8.00 Percent
Standard Deviation NA
Insufficient number of participants to calculate SD
|
8.18 Percent
Standard Deviation 14.077
|
1.30 Percent
Standard Deviation 0.000
|
8.88 Percent
Standard Deviation 2.724
|
|
Change From Baseline in Percent of White Blood Cells
NEUTROPHILS/LEUKOCYTES (%)
|
-20.69 Percent
Standard Deviation 8.997
|
-26.81 Percent
Standard Deviation 13.462
|
45.00 Percent
Standard Deviation NA
Insufficient number of participants to calculate SD
|
-12.13 Percent
Standard Deviation 30.712
|
-8.75 Percent
Standard Deviation 0.354
|
-35.55 Percent
Standard Deviation 11.865
|
SECONDARY outcome
Timeframe: 85 days after the dose of JCAR017 for Arms A, B, D, E, and F; 57 days after the dose of JCAR017 for Arm CPopulation: All treated participants with baseline and Day 85/Day 57 hematology laboratory values. Prespecified to be reported per Arm and not per cohort.
Change from baseline in erythrocyte (also known as red blood cell) numbers was measured using a test called a red blood cell count. Baseline is defined as the last measurement on or prior to any study treatment.
Outcome measures
| Measure |
Arm A: Cohort 1A and 1B JCAR017 Plus Durvalumab (Post-JCAR017 Infusion)
n=11 Participants
JCAR017 was administered at a dose of 50 x 10\^6 CAR+T cells (dose level 1 \[DL1\]) or 100 x 10\^6 CAR+T cells (DL2). On Day 29 after infusion, Durvalumab was administered at different doses and/ or schedules. Participants from both phases and all cohorts who reached a partial response 3 months after JCAR017 infusion could continue durvalumab until progression for a maximum total duration of 12 months.
|
Arm B: JCAR017 Plus CC-122 (Post-JCAR017 Infusion)
n=7 Participants
JCAR017 was administered at a dose of 100 x 10\^6 CAR+T cells (DL2). On Day 29 after infusion, CC-122 was administered at different doses. Participants who reach a partial response or stable disease 6 months (Day 180) after JCAR017 infusion could continue CC-122 until progression or for up to Month 24, whatever was earlier.
|
Arm C: JCAR017 Plus CC-220 (Iberdomide) (Post-JCAR017 Infusion)
n=1 Participants
JCAR017 was administered at a dose of 100 x 10\^6 CAR+T cells (DL2). Between Days 1 -21 post infusion, CC-220 was administered at different doses and/or schedules. Participants who reached a partial response or stable disease at Day 85 (Month 3) after JCAR017 infusion could continue CC-220 until progression or for up to Month 12, whichever was earlier.
|
Arm D: JCAR017 Plus Ibrutinib (Pre- and Post-JCAR017 Infusion)
n=12 Participants
Ibrutinib was administered at different doses on Day 1. On day 35, JCAR017 was administered at a dose of 100 x 10\^6 CAR+T cells (DL2), followed again by Ibrutinib at different doses. Participants received ibrutinib until 85 days post-infusion (Month 3).
|
Arm E: JCAR017 Plus Relatlimab and/or Nivolumab (Post-JCAR017 Infusion)
n=2 Participants
JCAR017 was administered at a dose of 100 x 10\^6 CAR+T cells (DL2). On day 8 or day 15 post infusion, relatlimab and nivolumab were administered at different doses and/or schedules. Participants received relatlimab and/or nivolumab until Day 85 (Month 3).
|
Arm F: Cohort 1A and 1D JCAR017 Plus CC-99282 (Post-JCAR017 Infusion)
n=4 Participants
JCAR017 was administered at a dose of 100 x 10\^6 CAR+T cells (DL2). On day 1, 8, or day 15 post infusion CC-99282 was administered at different doses and/or schedules. Participants received CC-99282 until Day 85 (Month 3).
|
|---|---|---|---|---|---|---|
|
Change From Baseline Erythrocyte Numbers
|
-0.11 10^12 cells/L
Standard Deviation 0.507
|
-0.21 10^12 cells/L
Standard Deviation 0.376
|
-0.34 10^12 cells/L
Standard Deviation NA
Insufficient number of participants to calculate SD
|
-0.10 10^12 cells/L
Standard Deviation 0.476
|
0.05 10^12 cells/L
Standard Deviation 0.148
|
-0.10 10^12 cells/L
Standard Deviation 0.281
|
SECONDARY outcome
Timeframe: 85 days after the dose of JCAR017 for Arms A, B, D, E, and F; 57 days after the dose of JCAR017 for Arm CPopulation: All treated participants with baseline and Day 85/Day 57 hematology laboratory values. Prespecified to be reported per Arm and not per cohort.
The change in the proportion of red blood cells in the blood was measured using a hematocrit test. A hematocrit test measures the volume of packed red blood cells relative to whole blood. This is represented as a ratio. Baseline is defined as the last measurement on or prior to any study treatment.
Outcome measures
| Measure |
Arm A: Cohort 1A and 1B JCAR017 Plus Durvalumab (Post-JCAR017 Infusion)
n=11 Participants
JCAR017 was administered at a dose of 50 x 10\^6 CAR+T cells (dose level 1 \[DL1\]) or 100 x 10\^6 CAR+T cells (DL2). On Day 29 after infusion, Durvalumab was administered at different doses and/ or schedules. Participants from both phases and all cohorts who reached a partial response 3 months after JCAR017 infusion could continue durvalumab until progression for a maximum total duration of 12 months.
|
Arm B: JCAR017 Plus CC-122 (Post-JCAR017 Infusion)
n=7 Participants
JCAR017 was administered at a dose of 100 x 10\^6 CAR+T cells (DL2). On Day 29 after infusion, CC-122 was administered at different doses. Participants who reach a partial response or stable disease 6 months (Day 180) after JCAR017 infusion could continue CC-122 until progression or for up to Month 24, whatever was earlier.
|
Arm C: JCAR017 Plus CC-220 (Iberdomide) (Post-JCAR017 Infusion)
n=1 Participants
JCAR017 was administered at a dose of 100 x 10\^6 CAR+T cells (DL2). Between Days 1 -21 post infusion, CC-220 was administered at different doses and/or schedules. Participants who reached a partial response or stable disease at Day 85 (Month 3) after JCAR017 infusion could continue CC-220 until progression or for up to Month 12, whichever was earlier.
|
Arm D: JCAR017 Plus Ibrutinib (Pre- and Post-JCAR017 Infusion)
n=12 Participants
Ibrutinib was administered at different doses on Day 1. On day 35, JCAR017 was administered at a dose of 100 x 10\^6 CAR+T cells (DL2), followed again by Ibrutinib at different doses. Participants received ibrutinib until 85 days post-infusion (Month 3).
|
Arm E: JCAR017 Plus Relatlimab and/or Nivolumab (Post-JCAR017 Infusion)
n=2 Participants
JCAR017 was administered at a dose of 100 x 10\^6 CAR+T cells (DL2). On day 8 or day 15 post infusion, relatlimab and nivolumab were administered at different doses and/or schedules. Participants received relatlimab and/or nivolumab until Day 85 (Month 3).
|
Arm F: Cohort 1A and 1D JCAR017 Plus CC-99282 (Post-JCAR017 Infusion)
n=4 Participants
JCAR017 was administered at a dose of 100 x 10\^6 CAR+T cells (DL2). On day 1, 8, or day 15 post infusion CC-99282 was administered at different doses and/or schedules. Participants received CC-99282 until Day 85 (Month 3).
|
|---|---|---|---|---|---|---|
|
Change From Baseline Hematocrit Ratio
|
0.01 Ratio
Standard Deviation 0.048
|
-0.02 Ratio
Standard Deviation 0.028
|
-0.04 Ratio
Standard Deviation NA
Insufficient number of participants to calculate SD
|
0.01 Ratio
Standard Deviation 0.048
|
0.02 Ratio
Standard Deviation 0.020
|
-0.01 Ratio
Standard Deviation 0.039
|
SECONDARY outcome
Timeframe: 85 days after the dose of JCAR017 for Arms A, B, D, E, and F; 57 days after the dose of JCAR017 for Arm CPopulation: All treated participants with baseline and Day 85/Day 57 hematology laboratory values. Prespecified to be reported per Arm and not per cohort.
The change from baseline in hemoglobin levels was measured using a hemoglobin test. A hemoglobin test measures the levels of hemoglobin in the blood. Hemoglobin is a protein in red blood cells that carries oxygen from the lungs to the rest of the body. Baseline is defined as the last measurement on or prior to any study treatment.
Outcome measures
| Measure |
Arm A: Cohort 1A and 1B JCAR017 Plus Durvalumab (Post-JCAR017 Infusion)
n=11 Participants
JCAR017 was administered at a dose of 50 x 10\^6 CAR+T cells (dose level 1 \[DL1\]) or 100 x 10\^6 CAR+T cells (DL2). On Day 29 after infusion, Durvalumab was administered at different doses and/ or schedules. Participants from both phases and all cohorts who reached a partial response 3 months after JCAR017 infusion could continue durvalumab until progression for a maximum total duration of 12 months.
|
Arm B: JCAR017 Plus CC-122 (Post-JCAR017 Infusion)
n=7 Participants
JCAR017 was administered at a dose of 100 x 10\^6 CAR+T cells (DL2). On Day 29 after infusion, CC-122 was administered at different doses. Participants who reach a partial response or stable disease 6 months (Day 180) after JCAR017 infusion could continue CC-122 until progression or for up to Month 24, whatever was earlier.
|
Arm C: JCAR017 Plus CC-220 (Iberdomide) (Post-JCAR017 Infusion)
n=1 Participants
JCAR017 was administered at a dose of 100 x 10\^6 CAR+T cells (DL2). Between Days 1 -21 post infusion, CC-220 was administered at different doses and/or schedules. Participants who reached a partial response or stable disease at Day 85 (Month 3) after JCAR017 infusion could continue CC-220 until progression or for up to Month 12, whichever was earlier.
|
Arm D: JCAR017 Plus Ibrutinib (Pre- and Post-JCAR017 Infusion)
n=12 Participants
Ibrutinib was administered at different doses on Day 1. On day 35, JCAR017 was administered at a dose of 100 x 10\^6 CAR+T cells (DL2), followed again by Ibrutinib at different doses. Participants received ibrutinib until 85 days post-infusion (Month 3).
|
Arm E: JCAR017 Plus Relatlimab and/or Nivolumab (Post-JCAR017 Infusion)
n=2 Participants
JCAR017 was administered at a dose of 100 x 10\^6 CAR+T cells (DL2). On day 8 or day 15 post infusion, relatlimab and nivolumab were administered at different doses and/or schedules. Participants received relatlimab and/or nivolumab until Day 85 (Month 3).
|
Arm F: Cohort 1A and 1D JCAR017 Plus CC-99282 (Post-JCAR017 Infusion)
n=4 Participants
JCAR017 was administered at a dose of 100 x 10\^6 CAR+T cells (DL2). On day 1, 8, or day 15 post infusion CC-99282 was administered at different doses and/or schedules. Participants received CC-99282 until Day 85 (Month 3).
|
|---|---|---|---|---|---|---|
|
Change From Baseline in Hemoglobin Levels
|
0.45 g/L
Standard Deviation 16.688
|
-5.43 g/L
Standard Deviation 12.869
|
-12.00 g/L
Standard Deviation NA
Insufficient number of participants to calculate SD
|
1.38 g/L
Standard Deviation 17.207
|
9.50 g/L
Standard Deviation 13.435
|
-2.50 g/L
Standard Deviation 18.502
|
SECONDARY outcome
Timeframe: 85 days after the dose of JCAR017 for Arms A, B, D, E, and F; 57 days after the dose of JCAR017 for Arm CPopulation: All treated participants with baseline and Day 85/Day 57 serum chemistry laboratory values. Prespecified to be reported per Arm and not per cohort.
Change from baseline in alanine aminotransferase (ALT) alkaline phosphatase (ALP), and aspartate aminotransferase (AST). Baseline is defined as the last measurement on or prior to any study treatment.
Outcome measures
| Measure |
Arm A: Cohort 1A and 1B JCAR017 Plus Durvalumab (Post-JCAR017 Infusion)
n=11 Participants
JCAR017 was administered at a dose of 50 x 10\^6 CAR+T cells (dose level 1 \[DL1\]) or 100 x 10\^6 CAR+T cells (DL2). On Day 29 after infusion, Durvalumab was administered at different doses and/ or schedules. Participants from both phases and all cohorts who reached a partial response 3 months after JCAR017 infusion could continue durvalumab until progression for a maximum total duration of 12 months.
|
Arm B: JCAR017 Plus CC-122 (Post-JCAR017 Infusion)
n=7 Participants
JCAR017 was administered at a dose of 100 x 10\^6 CAR+T cells (DL2). On Day 29 after infusion, CC-122 was administered at different doses. Participants who reach a partial response or stable disease 6 months (Day 180) after JCAR017 infusion could continue CC-122 until progression or for up to Month 24, whatever was earlier.
|
Arm C: JCAR017 Plus CC-220 (Iberdomide) (Post-JCAR017 Infusion)
n=1 Participants
JCAR017 was administered at a dose of 100 x 10\^6 CAR+T cells (DL2). Between Days 1 -21 post infusion, CC-220 was administered at different doses and/or schedules. Participants who reached a partial response or stable disease at Day 85 (Month 3) after JCAR017 infusion could continue CC-220 until progression or for up to Month 12, whichever was earlier.
|
Arm D: JCAR017 Plus Ibrutinib (Pre- and Post-JCAR017 Infusion)
n=12 Participants
Ibrutinib was administered at different doses on Day 1. On day 35, JCAR017 was administered at a dose of 100 x 10\^6 CAR+T cells (DL2), followed again by Ibrutinib at different doses. Participants received ibrutinib until 85 days post-infusion (Month 3).
|
Arm E: JCAR017 Plus Relatlimab and/or Nivolumab (Post-JCAR017 Infusion)
n=2 Participants
JCAR017 was administered at a dose of 100 x 10\^6 CAR+T cells (DL2). On day 8 or day 15 post infusion, relatlimab and nivolumab were administered at different doses and/or schedules. Participants received relatlimab and/or nivolumab until Day 85 (Month 3).
|
Arm F: Cohort 1A and 1D JCAR017 Plus CC-99282 (Post-JCAR017 Infusion)
n=4 Participants
JCAR017 was administered at a dose of 100 x 10\^6 CAR+T cells (DL2). On day 1, 8, or day 15 post infusion CC-99282 was administered at different doses and/or schedules. Participants received CC-99282 until Day 85 (Month 3).
|
|---|---|---|---|---|---|---|
|
Change From Baseline in Specific Liver Serum Enzyme Levels
ALANINE AMINOTRANSFERASE (U/L)
|
5.45 U/L
Standard Deviation 5.429
|
-2.86 U/L
Standard Deviation 7.105
|
-1.00 U/L
Standard Deviation NA
Insufficient number of participants to calculate SD
|
-0.58 U/L
Standard Deviation 11.237
|
0.50 U/L
Standard Deviation 4.950
|
2.50 U/L
Standard Deviation 2.082
|
|
Change From Baseline in Specific Liver Serum Enzyme Levels
ALKALINE PHOSPHATASE (U/L)
|
12.09 U/L
Standard Deviation 47.526
|
-2.43 U/L
Standard Deviation 24.234
|
22.00 U/L
Standard Deviation NA
Insufficient number of participants to calculate SD
|
-18.50 U/L
Standard Deviation 19.806
|
3.50 U/L
Standard Deviation 16.263
|
-16.25 U/L
Standard Deviation 11.295
|
|
Change From Baseline in Specific Liver Serum Enzyme Levels
ASPARTATE AMINOTRANSFERASE (U/L)
|
2.91 U/L
Standard Deviation 5.467
|
-4.43 U/L
Standard Deviation 6.373
|
-1.00 U/L
Standard Deviation NA
Insufficient number of participants to calculate SD
|
0.75 U/L
Standard Deviation 7.008
|
-5.50 U/L
Standard Deviation 17.678
|
-7.00 U/L
Standard Deviation 7.439
|
SECONDARY outcome
Timeframe: 85 days after the dose of JCAR017 for Arms A, B, D, E, and F; 57 days after the dose of JCAR017 for Arm CPopulation: All treated participants with baseline and Day 85/Day 57 serum chemistry laboratory values. Prespecified to be reported per Arm and not per cohort.
Change from baseline in serum albumin and protein levels. Serum protein level tests are blood tests that measure the number of proteins in the blood. Baseline is defined as the last measurement on or prior to any study treatment.
Outcome measures
| Measure |
Arm A: Cohort 1A and 1B JCAR017 Plus Durvalumab (Post-JCAR017 Infusion)
n=11 Participants
JCAR017 was administered at a dose of 50 x 10\^6 CAR+T cells (dose level 1 \[DL1\]) or 100 x 10\^6 CAR+T cells (DL2). On Day 29 after infusion, Durvalumab was administered at different doses and/ or schedules. Participants from both phases and all cohorts who reached a partial response 3 months after JCAR017 infusion could continue durvalumab until progression for a maximum total duration of 12 months.
|
Arm B: JCAR017 Plus CC-122 (Post-JCAR017 Infusion)
n=7 Participants
JCAR017 was administered at a dose of 100 x 10\^6 CAR+T cells (DL2). On Day 29 after infusion, CC-122 was administered at different doses. Participants who reach a partial response or stable disease 6 months (Day 180) after JCAR017 infusion could continue CC-122 until progression or for up to Month 24, whatever was earlier.
|
Arm C: JCAR017 Plus CC-220 (Iberdomide) (Post-JCAR017 Infusion)
n=1 Participants
JCAR017 was administered at a dose of 100 x 10\^6 CAR+T cells (DL2). Between Days 1 -21 post infusion, CC-220 was administered at different doses and/or schedules. Participants who reached a partial response or stable disease at Day 85 (Month 3) after JCAR017 infusion could continue CC-220 until progression or for up to Month 12, whichever was earlier.
|
Arm D: JCAR017 Plus Ibrutinib (Pre- and Post-JCAR017 Infusion)
n=12 Participants
Ibrutinib was administered at different doses on Day 1. On day 35, JCAR017 was administered at a dose of 100 x 10\^6 CAR+T cells (DL2), followed again by Ibrutinib at different doses. Participants received ibrutinib until 85 days post-infusion (Month 3).
|
Arm E: JCAR017 Plus Relatlimab and/or Nivolumab (Post-JCAR017 Infusion)
n=2 Participants
JCAR017 was administered at a dose of 100 x 10\^6 CAR+T cells (DL2). On day 8 or day 15 post infusion, relatlimab and nivolumab were administered at different doses and/or schedules. Participants received relatlimab and/or nivolumab until Day 85 (Month 3).
|
Arm F: Cohort 1A and 1D JCAR017 Plus CC-99282 (Post-JCAR017 Infusion)
n=4 Participants
JCAR017 was administered at a dose of 100 x 10\^6 CAR+T cells (DL2). On day 1, 8, or day 15 post infusion CC-99282 was administered at different doses and/or schedules. Participants received CC-99282 until Day 85 (Month 3).
|
|---|---|---|---|---|---|---|
|
Change From Baseline in Specific Serum Protein Levels
ALBUMIN (g/L)
|
4.09 g/L
Standard Deviation 5.281
|
2.29 g/L
Standard Deviation 3.450
|
9.00 g/L
Standard Deviation NA
Insufficient number of participants to calculate SD
|
1.42 g/L
Standard Deviation 4.926
|
6.00 g/L
Standard Deviation 4.243
|
3.50 g/L
Standard Deviation 9,747
|
|
Change From Baseline in Specific Serum Protein Levels
PROTEIN (g/L)
|
3.91 g/L
Standard Deviation 8.166
|
0.00 g/L
Standard Deviation 3.697
|
16.00 g/L
Standard Deviation NA
Insufficient number of participants to calculate SD
|
-4.17 g/L
Standard Deviation 3.881
|
-0.50 g/L
Standard Deviation 0.707
|
-2.50 g/L
Standard Deviation 11.030
|
SECONDARY outcome
Timeframe: 85 days after the dose of JCAR017 for Arms A, B, D, E, and F; 57 days after the dose of JCAR017 for Arm CPopulation: All treated participants with baseline and Day 85/Day 57 serum chemistry laboratory values. Prespecified to be reported per Arm and not per cohort.
Change from baseline in serum Beta-2-Microglobulin levels was measured using a beta-2 microglobulin (B2M) tumor marker test. Baseline is defined as the last measurement on or prior to any study treatment.
Outcome measures
| Measure |
Arm A: Cohort 1A and 1B JCAR017 Plus Durvalumab (Post-JCAR017 Infusion)
n=11 Participants
JCAR017 was administered at a dose of 50 x 10\^6 CAR+T cells (dose level 1 \[DL1\]) or 100 x 10\^6 CAR+T cells (DL2). On Day 29 after infusion, Durvalumab was administered at different doses and/ or schedules. Participants from both phases and all cohorts who reached a partial response 3 months after JCAR017 infusion could continue durvalumab until progression for a maximum total duration of 12 months.
|
Arm B: JCAR017 Plus CC-122 (Post-JCAR017 Infusion)
n=7 Participants
JCAR017 was administered at a dose of 100 x 10\^6 CAR+T cells (DL2). On Day 29 after infusion, CC-122 was administered at different doses. Participants who reach a partial response or stable disease 6 months (Day 180) after JCAR017 infusion could continue CC-122 until progression or for up to Month 24, whatever was earlier.
|
Arm C: JCAR017 Plus CC-220 (Iberdomide) (Post-JCAR017 Infusion)
n=1 Participants
JCAR017 was administered at a dose of 100 x 10\^6 CAR+T cells (DL2). Between Days 1 -21 post infusion, CC-220 was administered at different doses and/or schedules. Participants who reached a partial response or stable disease at Day 85 (Month 3) after JCAR017 infusion could continue CC-220 until progression or for up to Month 12, whichever was earlier.
|
Arm D: JCAR017 Plus Ibrutinib (Pre- and Post-JCAR017 Infusion)
n=12 Participants
Ibrutinib was administered at different doses on Day 1. On day 35, JCAR017 was administered at a dose of 100 x 10\^6 CAR+T cells (DL2), followed again by Ibrutinib at different doses. Participants received ibrutinib until 85 days post-infusion (Month 3).
|
Arm E: JCAR017 Plus Relatlimab and/or Nivolumab (Post-JCAR017 Infusion)
n=2 Participants
JCAR017 was administered at a dose of 100 x 10\^6 CAR+T cells (DL2). On day 8 or day 15 post infusion, relatlimab and nivolumab were administered at different doses and/or schedules. Participants received relatlimab and/or nivolumab until Day 85 (Month 3).
|
Arm F: Cohort 1A and 1D JCAR017 Plus CC-99282 (Post-JCAR017 Infusion)
n=4 Participants
JCAR017 was administered at a dose of 100 x 10\^6 CAR+T cells (DL2). On day 1, 8, or day 15 post infusion CC-99282 was administered at different doses and/or schedules. Participants received CC-99282 until Day 85 (Month 3).
|
|---|---|---|---|---|---|---|
|
Change From Baseline in Serum Beta-2-Microglobulin Levels
|
0.33 mg/L
Standard Deviation 0.735
|
0.06 mg/L
Standard Deviation 0.221
|
-0.10 mg/L
Standard Deviation NA
Insufficient number of participants to calculate SD
|
-0.04 mg/L
Standard Deviation 1.019
|
-0.65 mg/L
Standard Deviation 1.577
|
0.29 mg/L
Standard Deviation 0.654
|
SECONDARY outcome
Timeframe: 85 days after the dose of JCAR017 for Arms A, B, D, E, and F; 57 days after the dose of JCAR017 for Arm CPopulation: All treated participants with baseline and Day 85/Day 57 serum chemistry laboratory values. Prespecified to be reported per Arm and not per cohort.
Change from baseline in serum bicarbonate levels was measured using a serum bicarbonate test. Baseline is defined as the last measurement on or prior to any study treatment.
Outcome measures
| Measure |
Arm A: Cohort 1A and 1B JCAR017 Plus Durvalumab (Post-JCAR017 Infusion)
n=11 Participants
JCAR017 was administered at a dose of 50 x 10\^6 CAR+T cells (dose level 1 \[DL1\]) or 100 x 10\^6 CAR+T cells (DL2). On Day 29 after infusion, Durvalumab was administered at different doses and/ or schedules. Participants from both phases and all cohorts who reached a partial response 3 months after JCAR017 infusion could continue durvalumab until progression for a maximum total duration of 12 months.
|
Arm B: JCAR017 Plus CC-122 (Post-JCAR017 Infusion)
n=7 Participants
JCAR017 was administered at a dose of 100 x 10\^6 CAR+T cells (DL2). On Day 29 after infusion, CC-122 was administered at different doses. Participants who reach a partial response or stable disease 6 months (Day 180) after JCAR017 infusion could continue CC-122 until progression or for up to Month 24, whatever was earlier.
|
Arm C: JCAR017 Plus CC-220 (Iberdomide) (Post-JCAR017 Infusion)
n=1 Participants
JCAR017 was administered at a dose of 100 x 10\^6 CAR+T cells (DL2). Between Days 1 -21 post infusion, CC-220 was administered at different doses and/or schedules. Participants who reached a partial response or stable disease at Day 85 (Month 3) after JCAR017 infusion could continue CC-220 until progression or for up to Month 12, whichever was earlier.
|
Arm D: JCAR017 Plus Ibrutinib (Pre- and Post-JCAR017 Infusion)
n=12 Participants
Ibrutinib was administered at different doses on Day 1. On day 35, JCAR017 was administered at a dose of 100 x 10\^6 CAR+T cells (DL2), followed again by Ibrutinib at different doses. Participants received ibrutinib until 85 days post-infusion (Month 3).
|
Arm E: JCAR017 Plus Relatlimab and/or Nivolumab (Post-JCAR017 Infusion)
n=2 Participants
JCAR017 was administered at a dose of 100 x 10\^6 CAR+T cells (DL2). On day 8 or day 15 post infusion, relatlimab and nivolumab were administered at different doses and/or schedules. Participants received relatlimab and/or nivolumab until Day 85 (Month 3).
|
Arm F: Cohort 1A and 1D JCAR017 Plus CC-99282 (Post-JCAR017 Infusion)
n=4 Participants
JCAR017 was administered at a dose of 100 x 10\^6 CAR+T cells (DL2). On day 1, 8, or day 15 post infusion CC-99282 was administered at different doses and/or schedules. Participants received CC-99282 until Day 85 (Month 3).
|
|---|---|---|---|---|---|---|
|
Change From Baseline in Serum Bicarbonate Levels
|
0.91 mmol/L
Standard Deviation 3.270
|
0.00 mmol/L
Standard Deviation 4.509
|
0.00 mmol/L
Standard Deviation NA
Insufficient number of participants to calculate SD
|
-0.50 mmol/L
Standard Deviation 4.079
|
3 mmol/L
Standard Deviation 2.828
|
-0.50 mmol/L
Standard Deviation 2.646
|
SECONDARY outcome
Timeframe: 57 days after the dose of JCAR017Population: All treated participants with baseline and Day 57 coagulation laboratory values. Prespecified to be reported per Arm and not per cohort.
Change from baseline in activated partial thromboplastin and prothrombin times. Activated partial thromboplastin time and prothrombin time are blood tests that measure how long it takes for blood to form a clot. Baseline is defined as the last measurement on or prior to any study treatment.
Outcome measures
| Measure |
Arm A: Cohort 1A and 1B JCAR017 Plus Durvalumab (Post-JCAR017 Infusion)
n=12 Participants
JCAR017 was administered at a dose of 50 x 10\^6 CAR+T cells (dose level 1 \[DL1\]) or 100 x 10\^6 CAR+T cells (DL2). On Day 29 after infusion, Durvalumab was administered at different doses and/ or schedules. Participants from both phases and all cohorts who reached a partial response 3 months after JCAR017 infusion could continue durvalumab until progression for a maximum total duration of 12 months.
|
Arm B: JCAR017 Plus CC-122 (Post-JCAR017 Infusion)
n=7 Participants
JCAR017 was administered at a dose of 100 x 10\^6 CAR+T cells (DL2). On Day 29 after infusion, CC-122 was administered at different doses. Participants who reach a partial response or stable disease 6 months (Day 180) after JCAR017 infusion could continue CC-122 until progression or for up to Month 24, whatever was earlier.
|
Arm C: JCAR017 Plus CC-220 (Iberdomide) (Post-JCAR017 Infusion)
n=1 Participants
JCAR017 was administered at a dose of 100 x 10\^6 CAR+T cells (DL2). Between Days 1 -21 post infusion, CC-220 was administered at different doses and/or schedules. Participants who reached a partial response or stable disease at Day 85 (Month 3) after JCAR017 infusion could continue CC-220 until progression or for up to Month 12, whichever was earlier.
|
Arm D: JCAR017 Plus Ibrutinib (Pre- and Post-JCAR017 Infusion)
n=10 Participants
Ibrutinib was administered at different doses on Day 1. On day 35, JCAR017 was administered at a dose of 100 x 10\^6 CAR+T cells (DL2), followed again by Ibrutinib at different doses. Participants received ibrutinib until 85 days post-infusion (Month 3).
|
Arm E: JCAR017 Plus Relatlimab and/or Nivolumab (Post-JCAR017 Infusion)
n=2 Participants
JCAR017 was administered at a dose of 100 x 10\^6 CAR+T cells (DL2). On day 8 or day 15 post infusion, relatlimab and nivolumab were administered at different doses and/or schedules. Participants received relatlimab and/or nivolumab until Day 85 (Month 3).
|
Arm F: Cohort 1A and 1D JCAR017 Plus CC-99282 (Post-JCAR017 Infusion)
n=4 Participants
JCAR017 was administered at a dose of 100 x 10\^6 CAR+T cells (DL2). On day 1, 8, or day 15 post infusion CC-99282 was administered at different doses and/or schedules. Participants received CC-99282 until Day 85 (Month 3).
|
|---|---|---|---|---|---|---|
|
Change From Baseline in Coagulation Times
ACTIVATED PARTIAL THROMBOPLASTIN TIME (SEC)
|
-5.70 Seconds
Standard Deviation 21.348
|
-0.31 Seconds
Standard Deviation 5.423
|
2.40 Seconds
Standard Deviation NA
Insufficient number of participants to calculate SD.
|
-2.25 Seconds
Standard Deviation 1.566
|
4.25 Seconds
Standard Deviation 6.859
|
-2.10 Seconds
Standard Deviation 2.364
|
|
Change From Baseline in Coagulation Times
PROTHROMBIN TIME (SEC)
|
-0.02 Seconds
Standard Deviation 0.732
|
1.07 Seconds
Standard Deviation 2.974
|
0.40 Seconds
Standard Deviation NA
Insufficient number of participants to calculate SD.
|
-0.11 Seconds
Standard Deviation 0.479
|
-2.90 Seconds
Standard Deviation 3.394
|
0.98 Seconds
Standard Deviation 2.695
|
SECONDARY outcome
Timeframe: 57 days after the dose of JCAR017Population: All treated participants with baseline and Day 57 coagulation laboratory values. Prespecified to be reported per Arm and not per cohort.
D-dimer is a substance that is produced in the body when blood clots are broken down. The D-dimer laboratory test measures the level of D-dimer in the blood and is often used to help diagnose or rule out conditions related to blood clotting, such as deep vein thrombosis (DVT) or pulmonary embolism (PE). Elevated levels of D-dimer may indicate the presence of a blood clot, but other factors can also cause an increase in D-dimer levels. Therefore, the D-dimer test is typically used in combination with other diagnostic tests to help make an accurate diagnosis. Baseline is defined as the last measurement on or prior to any study treatment.
Outcome measures
| Measure |
Arm A: Cohort 1A and 1B JCAR017 Plus Durvalumab (Post-JCAR017 Infusion)
n=12 Participants
JCAR017 was administered at a dose of 50 x 10\^6 CAR+T cells (dose level 1 \[DL1\]) or 100 x 10\^6 CAR+T cells (DL2). On Day 29 after infusion, Durvalumab was administered at different doses and/ or schedules. Participants from both phases and all cohorts who reached a partial response 3 months after JCAR017 infusion could continue durvalumab until progression for a maximum total duration of 12 months.
|
Arm B: JCAR017 Plus CC-122 (Post-JCAR017 Infusion)
n=7 Participants
JCAR017 was administered at a dose of 100 x 10\^6 CAR+T cells (DL2). On Day 29 after infusion, CC-122 was administered at different doses. Participants who reach a partial response or stable disease 6 months (Day 180) after JCAR017 infusion could continue CC-122 until progression or for up to Month 24, whatever was earlier.
|
Arm C: JCAR017 Plus CC-220 (Iberdomide) (Post-JCAR017 Infusion)
n=1 Participants
JCAR017 was administered at a dose of 100 x 10\^6 CAR+T cells (DL2). Between Days 1 -21 post infusion, CC-220 was administered at different doses and/or schedules. Participants who reached a partial response or stable disease at Day 85 (Month 3) after JCAR017 infusion could continue CC-220 until progression or for up to Month 12, whichever was earlier.
|
Arm D: JCAR017 Plus Ibrutinib (Pre- and Post-JCAR017 Infusion)
n=10 Participants
Ibrutinib was administered at different doses on Day 1. On day 35, JCAR017 was administered at a dose of 100 x 10\^6 CAR+T cells (DL2), followed again by Ibrutinib at different doses. Participants received ibrutinib until 85 days post-infusion (Month 3).
|
Arm E: JCAR017 Plus Relatlimab and/or Nivolumab (Post-JCAR017 Infusion)
n=2 Participants
JCAR017 was administered at a dose of 100 x 10\^6 CAR+T cells (DL2). On day 8 or day 15 post infusion, relatlimab and nivolumab were administered at different doses and/or schedules. Participants received relatlimab and/or nivolumab until Day 85 (Month 3).
|
Arm F: Cohort 1A and 1D JCAR017 Plus CC-99282 (Post-JCAR017 Infusion)
n=4 Participants
JCAR017 was administered at a dose of 100 x 10\^6 CAR+T cells (DL2). On day 1, 8, or day 15 post infusion CC-99282 was administered at different doses and/or schedules. Participants received CC-99282 until Day 85 (Month 3).
|
|---|---|---|---|---|---|---|
|
Change From Baseline in D-Dimer Levels
|
-0.92 mg/L
Standard Deviation 1.789
|
-0.13 mg/L
Standard Deviation 0.311
|
-0.46 mg/L
Standard Deviation NA
Insufficient number of participants to calculate SD.
|
-0.69 mg/L
Standard Deviation 1.601
|
-0.39 mg/L
Standard Deviation 0.746
|
0.13 mg/L
Standard Deviation 0.241
|
SECONDARY outcome
Timeframe: 57 days after the dose of JCAR017Population: All treated participants with baseline and Day 57 coagulation laboratory values. Prespecified to be reported per Arm and not per cohort.
Fibrinogen is a protein that plays a role in a number of processes in the body, including blood clot formation, wound healing, inflammation, and blood vessel growth. Baseline is defined as the last measurement on or prior to any study treatment.
Outcome measures
| Measure |
Arm A: Cohort 1A and 1B JCAR017 Plus Durvalumab (Post-JCAR017 Infusion)
n=12 Participants
JCAR017 was administered at a dose of 50 x 10\^6 CAR+T cells (dose level 1 \[DL1\]) or 100 x 10\^6 CAR+T cells (DL2). On Day 29 after infusion, Durvalumab was administered at different doses and/ or schedules. Participants from both phases and all cohorts who reached a partial response 3 months after JCAR017 infusion could continue durvalumab until progression for a maximum total duration of 12 months.
|
Arm B: JCAR017 Plus CC-122 (Post-JCAR017 Infusion)
n=7 Participants
JCAR017 was administered at a dose of 100 x 10\^6 CAR+T cells (DL2). On Day 29 after infusion, CC-122 was administered at different doses. Participants who reach a partial response or stable disease 6 months (Day 180) after JCAR017 infusion could continue CC-122 until progression or for up to Month 24, whatever was earlier.
|
Arm C: JCAR017 Plus CC-220 (Iberdomide) (Post-JCAR017 Infusion)
n=1 Participants
JCAR017 was administered at a dose of 100 x 10\^6 CAR+T cells (DL2). Between Days 1 -21 post infusion, CC-220 was administered at different doses and/or schedules. Participants who reached a partial response or stable disease at Day 85 (Month 3) after JCAR017 infusion could continue CC-220 until progression or for up to Month 12, whichever was earlier.
|
Arm D: JCAR017 Plus Ibrutinib (Pre- and Post-JCAR017 Infusion)
n=10 Participants
Ibrutinib was administered at different doses on Day 1. On day 35, JCAR017 was administered at a dose of 100 x 10\^6 CAR+T cells (DL2), followed again by Ibrutinib at different doses. Participants received ibrutinib until 85 days post-infusion (Month 3).
|
Arm E: JCAR017 Plus Relatlimab and/or Nivolumab (Post-JCAR017 Infusion)
n=2 Participants
JCAR017 was administered at a dose of 100 x 10\^6 CAR+T cells (DL2). On day 8 or day 15 post infusion, relatlimab and nivolumab were administered at different doses and/or schedules. Participants received relatlimab and/or nivolumab until Day 85 (Month 3).
|
Arm F: Cohort 1A and 1D JCAR017 Plus CC-99282 (Post-JCAR017 Infusion)
n=4 Participants
JCAR017 was administered at a dose of 100 x 10\^6 CAR+T cells (DL2). On day 1, 8, or day 15 post infusion CC-99282 was administered at different doses and/or schedules. Participants received CC-99282 until Day 85 (Month 3).
|
|---|---|---|---|---|---|---|
|
Change From Baseline in Fibrinogen Levels
|
-0.23 g/L
Standard Deviation 1.379
|
-0.65 g/L
Standard Deviation 1.697
|
2.59 g/L
Standard Deviation NA
Insufficient number of participants to calculate SD.
|
-2.04 g/L
Standard Deviation 2.012
|
-5.12 g/L
Standard Deviation 1.888
|
-1.77 g/L
Standard Deviation 0.525
|
SECONDARY outcome
Timeframe: 57 days after the dose of JCAR017Population: All treated participants with baseline and Day 57 coagulation laboratory values. Prespecified to be reported per Arm and not per cohort.
The Prothrombin International Normalized Ratio (INR) is used to determine the clotting tendency of blood. The INR is derived from prothrombin time (PT) which is calculated as a ratio of the patient's PT to a control PT. Baseline is defined as the last measurement on or prior to any study treatment.
Outcome measures
| Measure |
Arm A: Cohort 1A and 1B JCAR017 Plus Durvalumab (Post-JCAR017 Infusion)
n=12 Participants
JCAR017 was administered at a dose of 50 x 10\^6 CAR+T cells (dose level 1 \[DL1\]) or 100 x 10\^6 CAR+T cells (DL2). On Day 29 after infusion, Durvalumab was administered at different doses and/ or schedules. Participants from both phases and all cohorts who reached a partial response 3 months after JCAR017 infusion could continue durvalumab until progression for a maximum total duration of 12 months.
|
Arm B: JCAR017 Plus CC-122 (Post-JCAR017 Infusion)
n=7 Participants
JCAR017 was administered at a dose of 100 x 10\^6 CAR+T cells (DL2). On Day 29 after infusion, CC-122 was administered at different doses. Participants who reach a partial response or stable disease 6 months (Day 180) after JCAR017 infusion could continue CC-122 until progression or for up to Month 24, whatever was earlier.
|
Arm C: JCAR017 Plus CC-220 (Iberdomide) (Post-JCAR017 Infusion)
n=1 Participants
JCAR017 was administered at a dose of 100 x 10\^6 CAR+T cells (DL2). Between Days 1 -21 post infusion, CC-220 was administered at different doses and/or schedules. Participants who reached a partial response or stable disease at Day 85 (Month 3) after JCAR017 infusion could continue CC-220 until progression or for up to Month 12, whichever was earlier.
|
Arm D: JCAR017 Plus Ibrutinib (Pre- and Post-JCAR017 Infusion)
n=10 Participants
Ibrutinib was administered at different doses on Day 1. On day 35, JCAR017 was administered at a dose of 100 x 10\^6 CAR+T cells (DL2), followed again by Ibrutinib at different doses. Participants received ibrutinib until 85 days post-infusion (Month 3).
|
Arm E: JCAR017 Plus Relatlimab and/or Nivolumab (Post-JCAR017 Infusion)
n=2 Participants
JCAR017 was administered at a dose of 100 x 10\^6 CAR+T cells (DL2). On day 8 or day 15 post infusion, relatlimab and nivolumab were administered at different doses and/or schedules. Participants received relatlimab and/or nivolumab until Day 85 (Month 3).
|
Arm F: Cohort 1A and 1D JCAR017 Plus CC-99282 (Post-JCAR017 Infusion)
n=4 Participants
JCAR017 was administered at a dose of 100 x 10\^6 CAR+T cells (DL2). On day 1, 8, or day 15 post infusion CC-99282 was administered at different doses and/or schedules. Participants received CC-99282 until Day 85 (Month 3).
|
|---|---|---|---|---|---|---|
|
Change From Baseline in Prothrombin International Normalized Ratio
|
-0.01 Ratio
Standard Deviation 0.079
|
0.08 Ratio
Standard Deviation 0.234
|
0.10 Ratio
Standard Deviation NA
Insufficient number of participants to calculate SD.
|
-0.01 Ratio
Standard Deviation 0.066
|
-0.20 Ratio
Standard Deviation 0.283
|
0.10 Ratio
Standard Deviation 0.198
|
SECONDARY outcome
Timeframe: From JCAR017 infusion to disease progression or death from any cause (up to approximately 62 months)Population: All participants in the combination treated set. The combination treated set included all participants who received an infusion of conforming JCAR017 cell product and at least one dose of the combination agent. Prespecified to be reported per Arm and not per cohort.
PFS is defined as time from JCAR017 infusion to disease progression or death from any cause. Progressive disease (PD) was measured using CT and PET as an increase in size index and non-index lesions, spleen size, and the presence of new lesions or diseased bone marrow. Summarized using Kaplan-Meier estimates.
Outcome measures
| Measure |
Arm A: Cohort 1A and 1B JCAR017 Plus Durvalumab (Post-JCAR017 Infusion)
n=14 Participants
JCAR017 was administered at a dose of 50 x 10\^6 CAR+T cells (dose level 1 \[DL1\]) or 100 x 10\^6 CAR+T cells (DL2). On Day 29 after infusion, Durvalumab was administered at different doses and/ or schedules. Participants from both phases and all cohorts who reached a partial response 3 months after JCAR017 infusion could continue durvalumab until progression for a maximum total duration of 12 months.
|
Arm B: JCAR017 Plus CC-122 (Post-JCAR017 Infusion)
n=8 Participants
JCAR017 was administered at a dose of 100 x 10\^6 CAR+T cells (DL2). On Day 29 after infusion, CC-122 was administered at different doses. Participants who reach a partial response or stable disease 6 months (Day 180) after JCAR017 infusion could continue CC-122 until progression or for up to Month 24, whatever was earlier.
|
Arm C: JCAR017 Plus CC-220 (Iberdomide) (Post-JCAR017 Infusion)
n=1 Participants
JCAR017 was administered at a dose of 100 x 10\^6 CAR+T cells (DL2). Between Days 1 -21 post infusion, CC-220 was administered at different doses and/or schedules. Participants who reached a partial response or stable disease at Day 85 (Month 3) after JCAR017 infusion could continue CC-220 until progression or for up to Month 12, whichever was earlier.
|
Arm D: JCAR017 Plus Ibrutinib (Pre- and Post-JCAR017 Infusion)
n=15 Participants
Ibrutinib was administered at different doses on Day 1. On day 35, JCAR017 was administered at a dose of 100 x 10\^6 CAR+T cells (DL2), followed again by Ibrutinib at different doses. Participants received ibrutinib until 85 days post-infusion (Month 3).
|
Arm E: JCAR017 Plus Relatlimab and/or Nivolumab (Post-JCAR017 Infusion)
n=2 Participants
JCAR017 was administered at a dose of 100 x 10\^6 CAR+T cells (DL2). On day 8 or day 15 post infusion, relatlimab and nivolumab were administered at different doses and/or schedules. Participants received relatlimab and/or nivolumab until Day 85 (Month 3).
|
Arm F: Cohort 1A and 1D JCAR017 Plus CC-99282 (Post-JCAR017 Infusion)
n=5 Participants
JCAR017 was administered at a dose of 100 x 10\^6 CAR+T cells (DL2). On day 1, 8, or day 15 post infusion CC-99282 was administered at different doses and/or schedules. Participants received CC-99282 until Day 85 (Month 3).
|
|---|---|---|---|---|---|---|
|
Progression-Free Survival (PFS)
|
20.90 Months
Interval 2.96 to
Upper CI could not be calculated due to insufficient number of events.
|
NA Months
Interval 2.3 to
PFS could not be calculated due to insufficient number of events.
|
2.86 Months
Upper and lower CI could not be calculated due to insufficient number of events.
|
NA Months
Interval 1.91 to
PFS could not be calculated due to insufficient number of events.
|
4.07 Months
Interval 2.17 to
Upper CI could not be calculated due to insufficient number of events.
|
3.06 Months
Interval 2.79 to
Upper CI could not be calculated due to insufficient number of events.
|
SECONDARY outcome
Timeframe: From start of JCAR017 to time of death from any cause, or data cut-off date, whichever occurred first (up to approximately 62 months)Population: All participants in the combination treated set. The combination treated set included all participants who received an infusion of conforming JCAR017 cell product and at least one dose of the combination agent. Prespecified to be reported per Arm and not per cohort.
Time from JCAR017 infusion to death. Data from surviving participants was censored at the last time that the participant was known to be alive. Summarized using Kaplan-Meier estimates.
Outcome measures
| Measure |
Arm A: Cohort 1A and 1B JCAR017 Plus Durvalumab (Post-JCAR017 Infusion)
n=14 Participants
JCAR017 was administered at a dose of 50 x 10\^6 CAR+T cells (dose level 1 \[DL1\]) or 100 x 10\^6 CAR+T cells (DL2). On Day 29 after infusion, Durvalumab was administered at different doses and/ or schedules. Participants from both phases and all cohorts who reached a partial response 3 months after JCAR017 infusion could continue durvalumab until progression for a maximum total duration of 12 months.
|
Arm B: JCAR017 Plus CC-122 (Post-JCAR017 Infusion)
n=8 Participants
JCAR017 was administered at a dose of 100 x 10\^6 CAR+T cells (DL2). On Day 29 after infusion, CC-122 was administered at different doses. Participants who reach a partial response or stable disease 6 months (Day 180) after JCAR017 infusion could continue CC-122 until progression or for up to Month 24, whatever was earlier.
|
Arm C: JCAR017 Plus CC-220 (Iberdomide) (Post-JCAR017 Infusion)
n=1 Participants
JCAR017 was administered at a dose of 100 x 10\^6 CAR+T cells (DL2). Between Days 1 -21 post infusion, CC-220 was administered at different doses and/or schedules. Participants who reached a partial response or stable disease at Day 85 (Month 3) after JCAR017 infusion could continue CC-220 until progression or for up to Month 12, whichever was earlier.
|
Arm D: JCAR017 Plus Ibrutinib (Pre- and Post-JCAR017 Infusion)
n=15 Participants
Ibrutinib was administered at different doses on Day 1. On day 35, JCAR017 was administered at a dose of 100 x 10\^6 CAR+T cells (DL2), followed again by Ibrutinib at different doses. Participants received ibrutinib until 85 days post-infusion (Month 3).
|
Arm E: JCAR017 Plus Relatlimab and/or Nivolumab (Post-JCAR017 Infusion)
n=2 Participants
JCAR017 was administered at a dose of 100 x 10\^6 CAR+T cells (DL2). On day 8 or day 15 post infusion, relatlimab and nivolumab were administered at different doses and/or schedules. Participants received relatlimab and/or nivolumab until Day 85 (Month 3).
|
Arm F: Cohort 1A and 1D JCAR017 Plus CC-99282 (Post-JCAR017 Infusion)
n=5 Participants
JCAR017 was administered at a dose of 100 x 10\^6 CAR+T cells (DL2). On day 1, 8, or day 15 post infusion CC-99282 was administered at different doses and/or schedules. Participants received CC-99282 until Day 85 (Month 3).
|
|---|---|---|---|---|---|---|
|
Overall Survival (OS)
|
31.34 Months
Interval 4.5 to 38.08
|
NA Months
Interval 3.22 to
Insufficient number of events to calculate Median OS and upper CI limit.
|
2.86 Months
Insufficient participants calculate lower and upper CI limits.
|
NA Months
Interval 9.46 to
Insufficient number of events to calculate Median OS and upper CI limit.
|
NA Months
Interval 7.26 to
Insufficient number of events to calculate Median OS and upper CI limit.
|
6.60 Months
Interval 4.27 to
Insufficient number of events to calculate upper CI limit.
|
SECONDARY outcome
Timeframe: At 1, 3, 6, 9, 12, 18 and 24 months post-JCAR017 infusionPopulation: All participants in the combination treated set. The combination treated set included all participants who received an infusion of conforming JCAR017 cell product and at least one dose of the combination agent. Prespecified to be reported per Arm and not per cohort.
The ORR is the percent of participants achieving an objective response of partial response (PR) or better according to the Lugano Criteria for Response Assessment (Cheson, 2014), prior to start of another non-study anticancer therapy. Complete response (CR) assessed by CT-scan: * Index lesions: Nodal Disease: ≤ 1.5 cm in largest transverse diameter, Extranodal Disease: Absent * Non-index lesions: Absent, * Spleen: \<13 cm * New lesions: None * Bone marrow: Normal Partial response (PR) assessed by CT-scan: * Index lesions: \>=50% decrease from baseline in shortest diameter * Non-index lesions: No increase, * Spleen: \>50% decrease from baseline in enlarged portion * New lesions: None * Bone marrow: N/A Overall Response (OR) = CR + PR
Outcome measures
| Measure |
Arm A: Cohort 1A and 1B JCAR017 Plus Durvalumab (Post-JCAR017 Infusion)
n=14 Participants
JCAR017 was administered at a dose of 50 x 10\^6 CAR+T cells (dose level 1 \[DL1\]) or 100 x 10\^6 CAR+T cells (DL2). On Day 29 after infusion, Durvalumab was administered at different doses and/ or schedules. Participants from both phases and all cohorts who reached a partial response 3 months after JCAR017 infusion could continue durvalumab until progression for a maximum total duration of 12 months.
|
Arm B: JCAR017 Plus CC-122 (Post-JCAR017 Infusion)
n=8 Participants
JCAR017 was administered at a dose of 100 x 10\^6 CAR+T cells (DL2). On Day 29 after infusion, CC-122 was administered at different doses. Participants who reach a partial response or stable disease 6 months (Day 180) after JCAR017 infusion could continue CC-122 until progression or for up to Month 24, whatever was earlier.
|
Arm C: JCAR017 Plus CC-220 (Iberdomide) (Post-JCAR017 Infusion)
n=1 Participants
JCAR017 was administered at a dose of 100 x 10\^6 CAR+T cells (DL2). Between Days 1 -21 post infusion, CC-220 was administered at different doses and/or schedules. Participants who reached a partial response or stable disease at Day 85 (Month 3) after JCAR017 infusion could continue CC-220 until progression or for up to Month 12, whichever was earlier.
|
Arm D: JCAR017 Plus Ibrutinib (Pre- and Post-JCAR017 Infusion)
n=15 Participants
Ibrutinib was administered at different doses on Day 1. On day 35, JCAR017 was administered at a dose of 100 x 10\^6 CAR+T cells (DL2), followed again by Ibrutinib at different doses. Participants received ibrutinib until 85 days post-infusion (Month 3).
|
Arm E: JCAR017 Plus Relatlimab and/or Nivolumab (Post-JCAR017 Infusion)
n=2 Participants
JCAR017 was administered at a dose of 100 x 10\^6 CAR+T cells (DL2). On day 8 or day 15 post infusion, relatlimab and nivolumab were administered at different doses and/or schedules. Participants received relatlimab and/or nivolumab until Day 85 (Month 3).
|
Arm F: Cohort 1A and 1D JCAR017 Plus CC-99282 (Post-JCAR017 Infusion)
n=5 Participants
JCAR017 was administered at a dose of 100 x 10\^6 CAR+T cells (DL2). On day 1, 8, or day 15 post infusion CC-99282 was administered at different doses and/or schedules. Participants received CC-99282 until Day 85 (Month 3).
|
|---|---|---|---|---|---|---|
|
Overall Response Rate (ORR)
Month 18
|
92.9 Percent of Participants
Interval 66.1 to 99.8
|
75.0 Percent of Participants
Interval 34.9 to 96.8
|
100.0 Percent of Participants
Interval 2.5 to 100.0
|
73.3 Percent of Participants
Interval 44.9 to 92.2
|
100.0 Percent of Participants
Interval 15.8 to 100.0
|
60.0 Percent of Participants
Interval 14.7 to 94.7
|
|
Overall Response Rate (ORR)
Month 24
|
92.9 Percent of Participants
Interval 66.1 to 99.8
|
75.0 Percent of Participants
Interval 34.9 to 96.8
|
100.0 Percent of Participants
Interval 2.5 to 100.0
|
73.3 Percent of Participants
Interval 44.9 to 92.2
|
100.0 Percent of Participants
Interval 15.8 to 100.0
|
60.0 Percent of Participants
Interval 14.7 to 94.7
|
|
Overall Response Rate (ORR)
Month 1
|
92.9 Percent of Participants
Interval 66.1 to 99.8
|
75.0 Percent of Participants
Interval 34.9 to 96.8
|
100.0 Percent of Participants
Interval 2.5 to 100.0
|
60.0 Percent of Participants
Interval 32.3 to 83.7
|
100.00 Percent of Participants
Interval 15.8 to 100.0
|
60.0 Percent of Participants
Interval 14.7 to 94.7
|
|
Overall Response Rate (ORR)
Month 3
|
92.9 Percent of Participants
Interval 66.1 to 99.8
|
75.0 Percent of Participants
Interval 34.9 to 96.8
|
100.0 Percent of Participants
Interval 2.5 to 100.0
|
73.3 Percent of Participants
Interval 44.9 to 92.2
|
100.0 Percent of Participants
Interval 15.8 to 100.0
|
60.0 Percent of Participants
Interval 14.7 to 94.7
|
|
Overall Response Rate (ORR)
Month 6
|
92.9 Percent of Participants
Interval 66.1 to 99.8
|
75.0 Percent of Participants
Interval 34.9 to 96.8
|
100.0 Percent of Participants
Interval 2.5 to 100.0
|
73.3 Percent of Participants
Interval 44.9 to 92.2
|
100.0 Percent of Participants
Interval 15.8 to 100.0
|
60.0 Percent of Participants
Interval 14.7 to 94.7
|
|
Overall Response Rate (ORR)
Month 9
|
92.9 Percent of Participants
Interval 66.1 to 99.8
|
75.0 Percent of Participants
Interval 34.9 to 96.8
|
100.0 Percent of Participants
Interval 2.5 to 100.0
|
73.3 Percent of Participants
Interval 44.9 to 92.2
|
100.0 Percent of Participants
Interval 15.8 to 100.0
|
60.0 Percent of Participants
Interval 14.7 to 94.7
|
|
Overall Response Rate (ORR)
Month 12
|
92.9 Percent of Participants
Interval 66.1 to 99.8
|
75.0 Percent of Participants
Interval 34.9 to 96.8
|
100.0 Percent of Participants
Interval 2.5 to 100.0
|
73.3 Percent of Participants
Interval 44.9 to 92.2
|
100.0 Percent of Participants
Interval 15.8 to 100.0
|
60.0 Percent of Participants
Interval 14.7 to 94.7
|
SECONDARY outcome
Timeframe: From JCAR017 infusion to disease progression or death from any cause (up to approximately 62 months)Population: All Responders in Combination Treated Set. The combination treated set included all participants who received an infusion of conforming JCAR017 cell product and at least one dose of the combination agent. Prespecified to be reported per Arm and not per cohort.
DOR is defined as the time from first response to disease progression or death from any cause. Summarized using Kaplan-Meier estimates.
Outcome measures
| Measure |
Arm A: Cohort 1A and 1B JCAR017 Plus Durvalumab (Post-JCAR017 Infusion)
n=13 Participants
JCAR017 was administered at a dose of 50 x 10\^6 CAR+T cells (dose level 1 \[DL1\]) or 100 x 10\^6 CAR+T cells (DL2). On Day 29 after infusion, Durvalumab was administered at different doses and/ or schedules. Participants from both phases and all cohorts who reached a partial response 3 months after JCAR017 infusion could continue durvalumab until progression for a maximum total duration of 12 months.
|
Arm B: JCAR017 Plus CC-122 (Post-JCAR017 Infusion)
n=6 Participants
JCAR017 was administered at a dose of 100 x 10\^6 CAR+T cells (DL2). On Day 29 after infusion, CC-122 was administered at different doses. Participants who reach a partial response or stable disease 6 months (Day 180) after JCAR017 infusion could continue CC-122 until progression or for up to Month 24, whatever was earlier.
|
Arm C: JCAR017 Plus CC-220 (Iberdomide) (Post-JCAR017 Infusion)
n=1 Participants
JCAR017 was administered at a dose of 100 x 10\^6 CAR+T cells (DL2). Between Days 1 -21 post infusion, CC-220 was administered at different doses and/or schedules. Participants who reached a partial response or stable disease at Day 85 (Month 3) after JCAR017 infusion could continue CC-220 until progression or for up to Month 12, whichever was earlier.
|
Arm D: JCAR017 Plus Ibrutinib (Pre- and Post-JCAR017 Infusion)
n=11 Participants
Ibrutinib was administered at different doses on Day 1. On day 35, JCAR017 was administered at a dose of 100 x 10\^6 CAR+T cells (DL2), followed again by Ibrutinib at different doses. Participants received ibrutinib until 85 days post-infusion (Month 3).
|
Arm E: JCAR017 Plus Relatlimab and/or Nivolumab (Post-JCAR017 Infusion)
n=2 Participants
JCAR017 was administered at a dose of 100 x 10\^6 CAR+T cells (DL2). On day 8 or day 15 post infusion, relatlimab and nivolumab were administered at different doses and/or schedules. Participants received relatlimab and/or nivolumab until Day 85 (Month 3).
|
Arm F: Cohort 1A and 1D JCAR017 Plus CC-99282 (Post-JCAR017 Infusion)
n=3 Participants
JCAR017 was administered at a dose of 100 x 10\^6 CAR+T cells (DL2). On day 1, 8, or day 15 post infusion CC-99282 was administered at different doses and/or schedules. Participants received CC-99282 until Day 85 (Month 3).
|
|---|---|---|---|---|---|---|
|
Duration of Response (DOR)
|
21.45 Months
Interval 2.43 to
Insufficient number of events to calculate upper CI limit.
|
NA Months
Interval 1.45 to
Insufficient number of events to calculate DoR and upper CI limit.
|
1.91 Months
Insufficient number of participants to calculate upper and lower CI limits.
|
NA Months
Interval 17.71 to
Insufficient number of events to calculate DoR upper CI limit.
|
3.15 Months
Interval 1.22 to
Insufficient number of events to calculate upper CI limit.
|
3.29 Months
Interval 1.87 to
Insufficient number of events to calculate upper CI limit
|
SECONDARY outcome
Timeframe: From JCAR017 infusion to disease progression or death from any cause (up to approximately 62 months)Population: All participants in the combination treated set. The combination treated set included all participants who received an infusion of conforming JCAR017 cell product and at least one dose of the combination agent. Prespecified to be reported per Arm and not per cohort.
EFS is defined as time from JCAR017 infusion to disease progression, starting a new antilymphoma therapy, or death from any cause, whichever occurred first.
Outcome measures
| Measure |
Arm A: Cohort 1A and 1B JCAR017 Plus Durvalumab (Post-JCAR017 Infusion)
n=14 Participants
JCAR017 was administered at a dose of 50 x 10\^6 CAR+T cells (dose level 1 \[DL1\]) or 100 x 10\^6 CAR+T cells (DL2). On Day 29 after infusion, Durvalumab was administered at different doses and/ or schedules. Participants from both phases and all cohorts who reached a partial response 3 months after JCAR017 infusion could continue durvalumab until progression for a maximum total duration of 12 months.
|
Arm B: JCAR017 Plus CC-122 (Post-JCAR017 Infusion)
n=8 Participants
JCAR017 was administered at a dose of 100 x 10\^6 CAR+T cells (DL2). On Day 29 after infusion, CC-122 was administered at different doses. Participants who reach a partial response or stable disease 6 months (Day 180) after JCAR017 infusion could continue CC-122 until progression or for up to Month 24, whatever was earlier.
|
Arm C: JCAR017 Plus CC-220 (Iberdomide) (Post-JCAR017 Infusion)
n=1 Participants
JCAR017 was administered at a dose of 100 x 10\^6 CAR+T cells (DL2). Between Days 1 -21 post infusion, CC-220 was administered at different doses and/or schedules. Participants who reached a partial response or stable disease at Day 85 (Month 3) after JCAR017 infusion could continue CC-220 until progression or for up to Month 12, whichever was earlier.
|
Arm D: JCAR017 Plus Ibrutinib (Pre- and Post-JCAR017 Infusion)
n=15 Participants
Ibrutinib was administered at different doses on Day 1. On day 35, JCAR017 was administered at a dose of 100 x 10\^6 CAR+T cells (DL2), followed again by Ibrutinib at different doses. Participants received ibrutinib until 85 days post-infusion (Month 3).
|
Arm E: JCAR017 Plus Relatlimab and/or Nivolumab (Post-JCAR017 Infusion)
n=2 Participants
JCAR017 was administered at a dose of 100 x 10\^6 CAR+T cells (DL2). On day 8 or day 15 post infusion, relatlimab and nivolumab were administered at different doses and/or schedules. Participants received relatlimab and/or nivolumab until Day 85 (Month 3).
|
Arm F: Cohort 1A and 1D JCAR017 Plus CC-99282 (Post-JCAR017 Infusion)
n=5 Participants
JCAR017 was administered at a dose of 100 x 10\^6 CAR+T cells (DL2). On day 1, 8, or day 15 post infusion CC-99282 was administered at different doses and/or schedules. Participants received CC-99282 until Day 85 (Month 3).
|
|---|---|---|---|---|---|---|
|
Event-Free Survival (EFS)
|
20.90 Months
Interval 2.96 to
Insufficient number of events to calculate upper CI limit.
|
NA Months
Interval 2.3 to
Insufficient number of events to calculate EFS and upper CI limit.
|
2.86 Months
Insufficient number of participants to calculate lower and upper CI limits.
|
18.76 Months
Interval 1.91 to
Insufficient number of events to calculate upper CI limit.
|
4.07 Months
Interval 2.17 to
Insufficient number of events to calculate upper CI limit.
|
3.06 Months
Interval 2.79 to
Insufficient number of events to calculate upper CI limit.
|
SECONDARY outcome
Timeframe: Up to 24 months post- JCAR017 infusionPopulation: All participants who received an infusion of conforming JCAR017 cell product with baseline and on-study PK measurements. Prespecified to be reported per Arm and not per cohort.
Cmax is the maximum or peak concentration of drug reached in the plasma following a dose of the drug. qPCR was used to determine Cmax by detecting the JCAR017 transgene.
Outcome measures
| Measure |
Arm A: Cohort 1A and 1B JCAR017 Plus Durvalumab (Post-JCAR017 Infusion)
n=15 Participants
JCAR017 was administered at a dose of 50 x 10\^6 CAR+T cells (dose level 1 \[DL1\]) or 100 x 10\^6 CAR+T cells (DL2). On Day 29 after infusion, Durvalumab was administered at different doses and/ or schedules. Participants from both phases and all cohorts who reached a partial response 3 months after JCAR017 infusion could continue durvalumab until progression for a maximum total duration of 12 months.
|
Arm B: JCAR017 Plus CC-122 (Post-JCAR017 Infusion)
n=10 Participants
JCAR017 was administered at a dose of 100 x 10\^6 CAR+T cells (DL2). On Day 29 after infusion, CC-122 was administered at different doses. Participants who reach a partial response or stable disease 6 months (Day 180) after JCAR017 infusion could continue CC-122 until progression or for up to Month 24, whatever was earlier.
|
Arm C: JCAR017 Plus CC-220 (Iberdomide) (Post-JCAR017 Infusion)
n=1 Participants
JCAR017 was administered at a dose of 100 x 10\^6 CAR+T cells (DL2). Between Days 1 -21 post infusion, CC-220 was administered at different doses and/or schedules. Participants who reached a partial response or stable disease at Day 85 (Month 3) after JCAR017 infusion could continue CC-220 until progression or for up to Month 12, whichever was earlier.
|
Arm D: JCAR017 Plus Ibrutinib (Pre- and Post-JCAR017 Infusion)
n=13 Participants
Ibrutinib was administered at different doses on Day 1. On day 35, JCAR017 was administered at a dose of 100 x 10\^6 CAR+T cells (DL2), followed again by Ibrutinib at different doses. Participants received ibrutinib until 85 days post-infusion (Month 3).
|
Arm E: JCAR017 Plus Relatlimab and/or Nivolumab (Post-JCAR017 Infusion)
n=2 Participants
JCAR017 was administered at a dose of 100 x 10\^6 CAR+T cells (DL2). On day 8 or day 15 post infusion, relatlimab and nivolumab were administered at different doses and/or schedules. Participants received relatlimab and/or nivolumab until Day 85 (Month 3).
|
Arm F: Cohort 1A and 1D JCAR017 Plus CC-99282 (Post-JCAR017 Infusion)
n=5 Participants
JCAR017 was administered at a dose of 100 x 10\^6 CAR+T cells (DL2). On day 1, 8, or day 15 post infusion CC-99282 was administered at different doses and/or schedules. Participants received CC-99282 until Day 85 (Month 3).
|
|---|---|---|---|---|---|---|
|
Maximum Concentration (Cmax) of JCAR017 by qPCR
|
11464.7 Copies/ug
Geometric Coefficient of Variation 305.8
|
14087.1 Copies/ug
Geometric Coefficient of Variation 434.7
|
28845.0 Copies/ug
Geometric Coefficient of Variation NA
Insufficient number of participants to calculate geometric CV.
|
28877.7 Copies/ug
Geometric Coefficient of Variation 314.2
|
58522.9 Copies/ug
Geometric Coefficient of Variation 63.5
|
18003.4 Copies/ug
Geometric Coefficient of Variation 343.4
|
SECONDARY outcome
Timeframe: Up to 24 months post- JCAR017 infusionPopulation: All participants who received an infusion of conforming JCAR017 cell product (JCAR017 PK analysis) or at least 1 dose of combination agent (combination agent analysis) with baseline and on-study PK measurements. Prespecified to be reported per Arm and not per cohort.
Time to maximum concentration (Tmax) is the time it takes for a drug to reach the maximum concentration (Cmax) after administration. qPCR was used to determine Tmax by detecting the JCAR017 transgene.
Outcome measures
| Measure |
Arm A: Cohort 1A and 1B JCAR017 Plus Durvalumab (Post-JCAR017 Infusion)
n=15 Participants
JCAR017 was administered at a dose of 50 x 10\^6 CAR+T cells (dose level 1 \[DL1\]) or 100 x 10\^6 CAR+T cells (DL2). On Day 29 after infusion, Durvalumab was administered at different doses and/ or schedules. Participants from both phases and all cohorts who reached a partial response 3 months after JCAR017 infusion could continue durvalumab until progression for a maximum total duration of 12 months.
|
Arm B: JCAR017 Plus CC-122 (Post-JCAR017 Infusion)
n=10 Participants
JCAR017 was administered at a dose of 100 x 10\^6 CAR+T cells (DL2). On Day 29 after infusion, CC-122 was administered at different doses. Participants who reach a partial response or stable disease 6 months (Day 180) after JCAR017 infusion could continue CC-122 until progression or for up to Month 24, whatever was earlier.
|
Arm C: JCAR017 Plus CC-220 (Iberdomide) (Post-JCAR017 Infusion)
n=1 Participants
JCAR017 was administered at a dose of 100 x 10\^6 CAR+T cells (DL2). Between Days 1 -21 post infusion, CC-220 was administered at different doses and/or schedules. Participants who reached a partial response or stable disease at Day 85 (Month 3) after JCAR017 infusion could continue CC-220 until progression or for up to Month 12, whichever was earlier.
|
Arm D: JCAR017 Plus Ibrutinib (Pre- and Post-JCAR017 Infusion)
n=13 Participants
Ibrutinib was administered at different doses on Day 1. On day 35, JCAR017 was administered at a dose of 100 x 10\^6 CAR+T cells (DL2), followed again by Ibrutinib at different doses. Participants received ibrutinib until 85 days post-infusion (Month 3).
|
Arm E: JCAR017 Plus Relatlimab and/or Nivolumab (Post-JCAR017 Infusion)
n=2 Participants
JCAR017 was administered at a dose of 100 x 10\^6 CAR+T cells (DL2). On day 8 or day 15 post infusion, relatlimab and nivolumab were administered at different doses and/or schedules. Participants received relatlimab and/or nivolumab until Day 85 (Month 3).
|
Arm F: Cohort 1A and 1D JCAR017 Plus CC-99282 (Post-JCAR017 Infusion)
n=5 Participants
JCAR017 was administered at a dose of 100 x 10\^6 CAR+T cells (DL2). On day 1, 8, or day 15 post infusion CC-99282 was administered at different doses and/or schedules. Participants received CC-99282 until Day 85 (Month 3).
|
|---|---|---|---|---|---|---|
|
Time to Maximum Concentration (Tmax) of JCAR017 by qPCR
|
10.0 Days
Interval 7.0 to 42.0
|
10.0 Days
Interval 7.0 to 19.0
|
29.0 Days
Interval 29.0 to 29.0
|
14.0 Days
Interval 7.0 to 28.0
|
10.0 Days
Interval 10.0 to 10.0
|
8.5 Days
Interval 7.0 to 10.0
|
SECONDARY outcome
Timeframe: Up to 24 months post- JCAR017 infusionPopulation: All participants who received an infusion of conforming JCAR017 cell product with baseline and on-study PK measurements. Prespecified to be reported per Arm and not per cohort.
Area Under the Curve" (AUC) represents the total exposure of participants to study drug. qPCR was used to determine AUC by detecting the JCAR017 transgene.
Outcome measures
| Measure |
Arm A: Cohort 1A and 1B JCAR017 Plus Durvalumab (Post-JCAR017 Infusion)
n=15 Participants
JCAR017 was administered at a dose of 50 x 10\^6 CAR+T cells (dose level 1 \[DL1\]) or 100 x 10\^6 CAR+T cells (DL2). On Day 29 after infusion, Durvalumab was administered at different doses and/ or schedules. Participants from both phases and all cohorts who reached a partial response 3 months after JCAR017 infusion could continue durvalumab until progression for a maximum total duration of 12 months.
|
Arm B: JCAR017 Plus CC-122 (Post-JCAR017 Infusion)
n=10 Participants
JCAR017 was administered at a dose of 100 x 10\^6 CAR+T cells (DL2). On Day 29 after infusion, CC-122 was administered at different doses. Participants who reach a partial response or stable disease 6 months (Day 180) after JCAR017 infusion could continue CC-122 until progression or for up to Month 24, whatever was earlier.
|
Arm C: JCAR017 Plus CC-220 (Iberdomide) (Post-JCAR017 Infusion)
n=1 Participants
JCAR017 was administered at a dose of 100 x 10\^6 CAR+T cells (DL2). Between Days 1 -21 post infusion, CC-220 was administered at different doses and/or schedules. Participants who reached a partial response or stable disease at Day 85 (Month 3) after JCAR017 infusion could continue CC-220 until progression or for up to Month 12, whichever was earlier.
|
Arm D: JCAR017 Plus Ibrutinib (Pre- and Post-JCAR017 Infusion)
n=13 Participants
Ibrutinib was administered at different doses on Day 1. On day 35, JCAR017 was administered at a dose of 100 x 10\^6 CAR+T cells (DL2), followed again by Ibrutinib at different doses. Participants received ibrutinib until 85 days post-infusion (Month 3).
|
Arm E: JCAR017 Plus Relatlimab and/or Nivolumab (Post-JCAR017 Infusion)
n=2 Participants
JCAR017 was administered at a dose of 100 x 10\^6 CAR+T cells (DL2). On day 8 or day 15 post infusion, relatlimab and nivolumab were administered at different doses and/or schedules. Participants received relatlimab and/or nivolumab until Day 85 (Month 3).
|
Arm F: Cohort 1A and 1D JCAR017 Plus CC-99282 (Post-JCAR017 Infusion)
n=5 Participants
JCAR017 was administered at a dose of 100 x 10\^6 CAR+T cells (DL2). On day 1, 8, or day 15 post infusion CC-99282 was administered at different doses and/or schedules. Participants received CC-99282 until Day 85 (Month 3).
|
|---|---|---|---|---|---|---|
|
Total Exposure to JCAR017 as Measured by the Area Under the Curve (AUC) by qPCR
|
85169.458 Copies/ug*day
Geometric Coefficient of Variation 237.850
|
83155.476 Copies/ug*day
Geometric Coefficient of Variation 473.149
|
288951.250 Copies/ug*day
Geometric Coefficient of Variation NA
Insufficient number of participants to calculate geometric CV.
|
281265.838 Copies/ug*day
Geometric Coefficient of Variation 360.545
|
529755.009 Copies/ug*day
Geometric Coefficient of Variation 9.534
|
190904.832 Copies/ug*day
Geometric Coefficient of Variation 224.399
|
Adverse Events
Arm A: Cohort 1A JCAR017 Plus Durvalumab (Post-JCAR017 Infusion)
Serious events: 4 serious events
Other events: 8 other events
Deaths: 7 deaths
Arm A: Cohort 1B JCAR017 Plus Durvalumab (Post-JCAR017 Infusion)
Serious events: 6 serious events
Other events: 8 other events
Deaths: 7 deaths
Arm B: Cohort 1A JCAR017 Plus CC-122 (Post-JCAR017 Infusion)
Serious events: 7 serious events
Other events: 11 other events
Deaths: 8 deaths
Arm C: Cohort 1A JCAR017 Plus CC-220 (Iberdomide) (Post-JCAR017 Infusion)
Serious events: 1 serious events
Other events: 1 other events
Deaths: 1 deaths
Arm D: Cohort 1A JCAR017 Plus Ibrutinib (Pre- and Post-JCAR017 Infusion)
Serious events: 6 serious events
Other events: 17 other events
Deaths: 5 deaths
Arm E: Cohort 1C JCAR017 Plus Relatlimab and/or Nivolumab (Post-JCAR017 Infusion)
Serious events: 2 serious events
Other events: 2 other events
Deaths: 1 deaths
Arm F: Cohort 1A Cohort 1A and 1D JCAR017 Plus CC-99282 (Post-JCAR017 Infusion)
Serious events: 3 serious events
Other events: 4 other events
Deaths: 4 deaths
Arm F: Cohort 1D Cohort 1A and 1D JCAR017 Plus CC-99282 (Post-JCAR017 Infusion)
Serious events: 0 serious events
Other events: 2 other events
Deaths: 1 deaths
Serious adverse events
| Measure |
Arm A: Cohort 1A JCAR017 Plus Durvalumab (Post-JCAR017 Infusion)
n=11 participants at risk
JCAR017 was administered at a dose of (50 x 10\^6 CAR+ T cells). On Day 29 after infusion, Durvalumab was administered at a low dose. On day 43 after infusion Durvalumab was administered at a mid-dose and on days 57 and 85 after infusion was administered at a high dose. Participants who reached a partial response 3 months after JCAR017 infusion could continue Durvalumab until progression for a maximum total duration of 12 months.
|
Arm A: Cohort 1B JCAR017 Plus Durvalumab (Post-JCAR017 Infusion)
n=9 participants at risk
JCAR017 was administered at a dose of (100 x 10\^6 CAR+ T cells). On Day 29 after infusion, Durvalumab was administered at a low dose. On day 43 after infusion Durvalumab was administered at a mid-dose and on days 57 and 85 after infusion was administered at a high dose. Participants who reached a partial response 3 months after JCAR017 infusion could continue Durvalumab until progression for a maximum total duration of 12 months.
|
Arm B: Cohort 1A JCAR017 Plus CC-122 (Post-JCAR017 Infusion)
n=13 participants at risk
JCAR017 was administered at a dose of 100 x 10\^6 CAR+T cells. Between days 29 and 180 after infusion participants received a standard dose of CC-122, 5 out of 7 days. Participants who reached a partial response or stable disease 6 months (Day 180) after JCAR017 infusion could continue CC-122 until progression or for up to Month 24, whatever was earlier.
|
Arm C: Cohort 1A JCAR017 Plus CC-220 (Iberdomide) (Post-JCAR017 Infusion)
n=1 participants at risk
JCAR017 was administered at a dose of 100 x 10\^6 CAR+T cells. Between Days 15 -21 post infusion, CC-220 was administered at a standard dose. Participants who reached a partial response or stable disease at Day 85 (Month 3) after JCAR017 infusion could continue CC-220 until progression or for up to Month 12, whichever was earlier.
|
Arm D: Cohort 1A JCAR017 Plus Ibrutinib (Pre- and Post-JCAR017 Infusion)
n=17 participants at risk
Ibrutinib was administered from 35 days before to 85 days post JCAR017 infusion which was administered at a dose of 100 x 10\^6 CAR+T cells. Participants received ibrutinib until 85 days post-infusion (Month 3).
|
Arm E: Cohort 1C JCAR017 Plus Relatlimab and/or Nivolumab (Post-JCAR017 Infusion)
n=2 participants at risk
JCAR017 was administered at a dose of 100 x 10\^6 CAR+T cells. On days 8, 22, 36 post infusion, nivolumab was administered at a low dose. On days 57 and 85 post infusion, participants received nivolumab at a higher dose. Participants received nivolumab until Day 85 (Month 3).
|
Arm F: Cohort 1A Cohort 1A and 1D JCAR017 Plus CC-99282 (Post-JCAR017 Infusion)
n=7 participants at risk
JCAR017 was administered at a dose of (100 x 10\^6 CAR+ T cells). Starting on Day 8 post infusion, CC-99282 was administered every 7 days. Participants received CC-99282 until Day 85 (Month 3)
|
Arm F: Cohort 1D Cohort 1A and 1D JCAR017 Plus CC-99282 (Post-JCAR017 Infusion)
n=2 participants at risk
JCAR017 was administered at a dose of (100 x 10\^6 CAR+ T cells). Starting on Day 1 post infusion, CC-99282 was administered every 7 days. Participants received CC-99282 until Day 85 (Month 3)
|
|---|---|---|---|---|---|---|---|---|
|
Nervous system disorders
Haemorrhage intracranial
|
0.00%
0/11 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/9 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
7.7%
1/13 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/1 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/17 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/2 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/7 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/2 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
|
Blood and lymphatic system disorders
Anaemia
|
0.00%
0/11 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
11.1%
1/9 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/13 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/1 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/17 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/2 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/7 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/2 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
|
Blood and lymphatic system disorders
Febrile neutropenia
|
9.1%
1/11 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/9 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
7.7%
1/13 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/1 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
11.8%
2/17 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/2 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/7 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/2 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
|
Blood and lymphatic system disorders
Thrombocytopenia
|
0.00%
0/11 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
22.2%
2/9 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/13 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/1 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/17 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/2 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/7 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/2 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
|
Cardiac disorders
Arrhythmia
|
0.00%
0/11 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
11.1%
1/9 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/13 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/1 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/17 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/2 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/7 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/2 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
|
Gastrointestinal disorders
Abdominal pain
|
0.00%
0/11 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/9 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/13 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/1 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/17 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
50.0%
1/2 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/7 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/2 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
|
Gastrointestinal disorders
Colitis ischaemic
|
0.00%
0/11 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/9 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
7.7%
1/13 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/1 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/17 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/2 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/7 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/2 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
|
Gastrointestinal disorders
Constipation
|
0.00%
0/11 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/9 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/13 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/1 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/17 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
50.0%
1/2 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/7 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/2 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
|
Gastrointestinal disorders
Enteritis
|
0.00%
0/11 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/9 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/13 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/1 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
5.9%
1/17 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/2 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/7 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/2 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
|
Gastrointestinal disorders
Gastrointestinal haemorrhage
|
0.00%
0/11 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
11.1%
1/9 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
7.7%
1/13 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/1 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/17 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/2 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/7 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/2 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
|
General disorders
Pain
|
0.00%
0/11 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/9 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/13 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
100.0%
1/1 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/17 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/2 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/7 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/2 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
|
General disorders
Pyrexia
|
9.1%
1/11 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/9 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/13 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/1 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/17 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/2 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/7 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/2 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
|
Hepatobiliary disorders
Hyperbilirubinaemia
|
0.00%
0/11 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
11.1%
1/9 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
7.7%
1/13 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/1 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/17 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/2 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/7 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/2 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
|
Immune system disorders
Cytokine release syndrome
|
0.00%
0/11 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
11.1%
1/9 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
23.1%
3/13 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/1 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/17 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/2 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/7 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/2 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
|
Infections and infestations
COVID-19
|
0.00%
0/11 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/9 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/13 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/1 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
5.9%
1/17 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/2 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
14.3%
1/7 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/2 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
|
Infections and infestations
Cellulitis
|
9.1%
1/11 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/9 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/13 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/1 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/17 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/2 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/7 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/2 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
|
Infections and infestations
Influenza
|
0.00%
0/11 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/9 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
7.7%
1/13 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/1 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/17 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/2 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/7 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/2 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
|
Infections and infestations
Pneumonia
|
0.00%
0/11 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
11.1%
1/9 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
7.7%
1/13 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/1 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
5.9%
1/17 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/2 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/7 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/2 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
|
Infections and infestations
Respiratory syncytial virus infection
|
9.1%
1/11 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/9 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/13 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/1 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/17 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/2 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/7 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/2 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
|
Infections and infestations
Sepsis
|
9.1%
1/11 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
11.1%
1/9 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/13 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/1 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/17 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/2 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/7 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/2 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
|
Infections and infestations
Staphylococcal sepsis
|
0.00%
0/11 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
11.1%
1/9 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/13 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/1 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/17 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/2 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/7 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/2 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
|
Infections and infestations
Upper respiratory tract infection
|
0.00%
0/11 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
11.1%
1/9 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/13 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/1 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/17 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/2 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/7 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/2 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
|
Metabolism and nutrition disorders
Failure to thrive
|
0.00%
0/11 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/9 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/13 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
100.0%
1/1 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/17 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/2 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/7 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/2 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
|
Metabolism and nutrition disorders
Hypercalcaemia
|
0.00%
0/11 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/9 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/13 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/1 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
5.9%
1/17 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/2 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/7 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/2 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
|
Metabolism and nutrition disorders
Hypervolaemia
|
0.00%
0/11 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/9 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
7.7%
1/13 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/1 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/17 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/2 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/7 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/2 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Colon cancer stage 0
|
0.00%
0/11 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
11.1%
1/9 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/13 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/1 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/17 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/2 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/7 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/2 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Squamous cell carcinoma of skin
|
9.1%
1/11 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/9 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/13 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/1 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/17 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/2 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/7 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/2 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
|
Nervous system disorders
Agraphia
|
0.00%
0/11 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/9 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/13 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/1 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
5.9%
1/17 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/2 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/7 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/2 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
|
Nervous system disorders
Encephalopathy
|
9.1%
1/11 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/9 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/13 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/1 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/17 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/2 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/7 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/2 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
|
Nervous system disorders
Headache
|
0.00%
0/11 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/9 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/13 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/1 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/17 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/2 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
14.3%
1/7 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/2 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
|
Nervous system disorders
Neurotoxicity
|
9.1%
1/11 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
11.1%
1/9 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
15.4%
2/13 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/1 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
11.8%
2/17 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
50.0%
1/2 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
14.3%
1/7 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/2 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
|
Psychiatric disorders
Mental status changes
|
0.00%
0/11 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
11.1%
1/9 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/13 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/1 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/17 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/2 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/7 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/2 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
|
Renal and urinary disorders
Acute kidney injury
|
9.1%
1/11 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
22.2%
2/9 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/13 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/1 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/17 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/2 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/7 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/2 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
|
Respiratory, thoracic and mediastinal disorders
Acute respiratory failure
|
9.1%
1/11 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
11.1%
1/9 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/13 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/1 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/17 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/2 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/7 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/2 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
|
Respiratory, thoracic and mediastinal disorders
Pleural effusion
|
0.00%
0/11 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/9 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/13 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/1 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
5.9%
1/17 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/2 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/7 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/2 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
|
Skin and subcutaneous tissue disorders
Rash maculo-papular
|
9.1%
1/11 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/9 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/13 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/1 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/17 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/2 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/7 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/2 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
|
Blood and lymphatic system disorders
Neutropenia
|
0.00%
0/11 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/9 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/13 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/1 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
5.9%
1/17 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/2 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/7 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/2 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
|
Gastrointestinal disorders
Large intestine perforation
|
0.00%
0/11 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/9 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/13 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/1 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
5.9%
1/17 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/2 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/7 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/2 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
Other adverse events
| Measure |
Arm A: Cohort 1A JCAR017 Plus Durvalumab (Post-JCAR017 Infusion)
n=11 participants at risk
JCAR017 was administered at a dose of (50 x 10\^6 CAR+ T cells). On Day 29 after infusion, Durvalumab was administered at a low dose. On day 43 after infusion Durvalumab was administered at a mid-dose and on days 57 and 85 after infusion was administered at a high dose. Participants who reached a partial response 3 months after JCAR017 infusion could continue Durvalumab until progression for a maximum total duration of 12 months.
|
Arm A: Cohort 1B JCAR017 Plus Durvalumab (Post-JCAR017 Infusion)
n=9 participants at risk
JCAR017 was administered at a dose of (100 x 10\^6 CAR+ T cells). On Day 29 after infusion, Durvalumab was administered at a low dose. On day 43 after infusion Durvalumab was administered at a mid-dose and on days 57 and 85 after infusion was administered at a high dose. Participants who reached a partial response 3 months after JCAR017 infusion could continue Durvalumab until progression for a maximum total duration of 12 months.
|
Arm B: Cohort 1A JCAR017 Plus CC-122 (Post-JCAR017 Infusion)
n=13 participants at risk
JCAR017 was administered at a dose of 100 x 10\^6 CAR+T cells. Between days 29 and 180 after infusion participants received a standard dose of CC-122, 5 out of 7 days. Participants who reached a partial response or stable disease 6 months (Day 180) after JCAR017 infusion could continue CC-122 until progression or for up to Month 24, whatever was earlier.
|
Arm C: Cohort 1A JCAR017 Plus CC-220 (Iberdomide) (Post-JCAR017 Infusion)
n=1 participants at risk
JCAR017 was administered at a dose of 100 x 10\^6 CAR+T cells. Between Days 15 -21 post infusion, CC-220 was administered at a standard dose. Participants who reached a partial response or stable disease at Day 85 (Month 3) after JCAR017 infusion could continue CC-220 until progression or for up to Month 12, whichever was earlier.
|
Arm D: Cohort 1A JCAR017 Plus Ibrutinib (Pre- and Post-JCAR017 Infusion)
n=17 participants at risk
Ibrutinib was administered from 35 days before to 85 days post JCAR017 infusion which was administered at a dose of 100 x 10\^6 CAR+T cells. Participants received ibrutinib until 85 days post-infusion (Month 3).
|
Arm E: Cohort 1C JCAR017 Plus Relatlimab and/or Nivolumab (Post-JCAR017 Infusion)
n=2 participants at risk
JCAR017 was administered at a dose of 100 x 10\^6 CAR+T cells. On days 8, 22, 36 post infusion, nivolumab was administered at a low dose. On days 57 and 85 post infusion, participants received nivolumab at a higher dose. Participants received nivolumab until Day 85 (Month 3).
|
Arm F: Cohort 1A Cohort 1A and 1D JCAR017 Plus CC-99282 (Post-JCAR017 Infusion)
n=7 participants at risk
JCAR017 was administered at a dose of (100 x 10\^6 CAR+ T cells). Starting on Day 8 post infusion, CC-99282 was administered every 7 days. Participants received CC-99282 until Day 85 (Month 3)
|
Arm F: Cohort 1D Cohort 1A and 1D JCAR017 Plus CC-99282 (Post-JCAR017 Infusion)
n=2 participants at risk
JCAR017 was administered at a dose of (100 x 10\^6 CAR+ T cells). Starting on Day 1 post infusion, CC-99282 was administered every 7 days. Participants received CC-99282 until Day 85 (Month 3)
|
|---|---|---|---|---|---|---|---|---|
|
Blood and lymphatic system disorders
Anaemia
|
27.3%
3/11 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
77.8%
7/9 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
38.5%
5/13 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
100.0%
1/1 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
58.8%
10/17 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
100.0%
2/2 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
28.6%
2/7 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
50.0%
1/2 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
|
Blood and lymphatic system disorders
Haemolytic anaemia
|
0.00%
0/11 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
11.1%
1/9 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/13 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/1 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/17 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/2 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/7 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/2 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
|
Blood and lymphatic system disorders
Hypofibrinogenaemia
|
0.00%
0/11 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/9 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/13 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
100.0%
1/1 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
5.9%
1/17 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/2 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/7 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/2 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
|
Blood and lymphatic system disorders
Leukocytosis
|
0.00%
0/11 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
11.1%
1/9 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/13 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/1 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/17 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/2 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/7 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/2 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
|
Blood and lymphatic system disorders
Leukopenia
|
27.3%
3/11 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
33.3%
3/9 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
30.8%
4/13 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/1 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/17 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
50.0%
1/2 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/7 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/2 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
|
Blood and lymphatic system disorders
Lymphopenia
|
9.1%
1/11 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
11.1%
1/9 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
23.1%
3/13 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/1 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/17 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/2 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/7 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/2 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
|
Blood and lymphatic system disorders
Neutropenia
|
18.2%
2/11 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
55.6%
5/9 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
61.5%
8/13 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
100.0%
1/1 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
29.4%
5/17 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
100.0%
2/2 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
14.3%
1/7 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/2 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
|
Blood and lymphatic system disorders
Thrombocytopenia
|
36.4%
4/11 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
44.4%
4/9 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
53.8%
7/13 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
100.0%
1/1 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
11.8%
2/17 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
100.0%
2/2 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/7 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/2 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
|
Cardiac disorders
Atrial fibrillation
|
0.00%
0/11 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/9 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
7.7%
1/13 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/1 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
5.9%
1/17 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/2 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/7 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/2 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
|
Cardiac disorders
Extrasystoles
|
0.00%
0/11 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/9 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/13 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/1 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
5.9%
1/17 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/2 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/7 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/2 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
|
Cardiac disorders
Palpitations
|
0.00%
0/11 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/9 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/13 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/1 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/17 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/2 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
14.3%
1/7 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/2 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
|
Cardiac disorders
Sinus tachycardia
|
0.00%
0/11 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/9 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
7.7%
1/13 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
100.0%
1/1 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/17 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
50.0%
1/2 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/7 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/2 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
|
Cardiac disorders
Supraventricular extrasystoles
|
0.00%
0/11 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/9 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/13 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/1 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
5.9%
1/17 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/2 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/7 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/2 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
|
Cardiac disorders
Tachycardia
|
0.00%
0/11 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
11.1%
1/9 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/13 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/1 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
11.8%
2/17 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/2 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/7 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/2 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
|
Cardiac disorders
Ventricular tachycardia
|
0.00%
0/11 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
11.1%
1/9 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/13 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/1 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
5.9%
1/17 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/2 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/7 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/2 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
|
Ear and labyrinth disorders
Cerumen impaction
|
0.00%
0/11 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/9 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
7.7%
1/13 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/1 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/17 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/2 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/7 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/2 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
|
Endocrine disorders
Hypothyroidism
|
0.00%
0/11 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
11.1%
1/9 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/13 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/1 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/17 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
50.0%
1/2 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/7 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/2 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
|
Eye disorders
Conjunctival haemorrhage
|
0.00%
0/11 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/9 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/13 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/1 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
11.8%
2/17 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/2 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/7 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/2 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
|
Eye disorders
Dry eye
|
0.00%
0/11 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/9 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
7.7%
1/13 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/1 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/17 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/2 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
14.3%
1/7 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/2 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
|
Eye disorders
Eye irritation
|
0.00%
0/11 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/9 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/13 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/1 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/17 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
50.0%
1/2 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/7 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/2 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
|
Eye disorders
Periorbital oedema
|
0.00%
0/11 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/9 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/13 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/1 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
5.9%
1/17 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/2 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/7 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/2 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
|
Eye disorders
Vision blurred
|
0.00%
0/11 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
22.2%
2/9 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/13 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/1 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/17 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/2 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/7 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/2 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
|
Eye disorders
Visual impairment
|
0.00%
0/11 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/9 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/13 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/1 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
5.9%
1/17 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/2 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/7 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/2 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
|
Eye disorders
Vitreous floaters
|
0.00%
0/11 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
11.1%
1/9 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/13 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/1 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/17 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/2 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/7 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/2 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
|
Gastrointestinal disorders
Abdominal distension
|
0.00%
0/11 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
11.1%
1/9 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
7.7%
1/13 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/1 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
5.9%
1/17 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/2 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/7 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/2 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
|
Gastrointestinal disorders
Abdominal pain
|
9.1%
1/11 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
11.1%
1/9 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
7.7%
1/13 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
100.0%
1/1 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
5.9%
1/17 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
50.0%
1/2 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/7 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/2 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
|
Gastrointestinal disorders
Abdominal pain upper
|
9.1%
1/11 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
11.1%
1/9 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/13 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/1 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/17 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/2 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/7 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/2 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
|
Gastrointestinal disorders
Anal incontinence
|
0.00%
0/11 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/9 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/13 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
100.0%
1/1 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
5.9%
1/17 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/2 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/7 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/2 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
|
Gastrointestinal disorders
Chapped lips
|
9.1%
1/11 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/9 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/13 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/1 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/17 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/2 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/7 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/2 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
|
Gastrointestinal disorders
Constipation
|
0.00%
0/11 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
33.3%
3/9 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
23.1%
3/13 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
100.0%
1/1 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
5.9%
1/17 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/2 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/7 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/2 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
|
Gastrointestinal disorders
Diarrhoea
|
0.00%
0/11 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
11.1%
1/9 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
23.1%
3/13 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/1 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
17.6%
3/17 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
50.0%
1/2 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
14.3%
1/7 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
50.0%
1/2 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
|
Gastrointestinal disorders
Dry mouth
|
0.00%
0/11 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
11.1%
1/9 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
7.7%
1/13 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/1 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
5.9%
1/17 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/2 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/7 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/2 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
|
Gastrointestinal disorders
Dyspepsia
|
0.00%
0/11 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/9 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/13 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/1 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/17 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/2 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
14.3%
1/7 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/2 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
|
Gastrointestinal disorders
Enterocolitis
|
9.1%
1/11 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/9 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/13 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/1 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/17 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/2 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/7 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/2 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
|
Gastrointestinal disorders
Flatulence
|
0.00%
0/11 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
11.1%
1/9 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/13 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/1 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/17 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/2 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/7 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/2 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
|
Gastrointestinal disorders
Gastrointestinal disorder
|
0.00%
0/11 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/9 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/13 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/1 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
5.9%
1/17 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/2 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/7 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/2 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
|
Gastrointestinal disorders
Gastrooesophageal reflux disease
|
0.00%
0/11 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/9 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
7.7%
1/13 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/1 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/17 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/2 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/7 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/2 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
|
Gastrointestinal disorders
Hiatus hernia
|
9.1%
1/11 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/9 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/13 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/1 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/17 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/2 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/7 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/2 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
|
Gastrointestinal disorders
Ileus
|
0.00%
0/11 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/9 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
7.7%
1/13 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/1 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/17 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/2 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/7 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/2 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
|
Gastrointestinal disorders
Ileus paralytic
|
9.1%
1/11 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/9 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/13 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/1 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/17 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/2 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/7 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/2 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
|
Gastrointestinal disorders
Mesenteric artery stenosis
|
0.00%
0/11 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/9 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
7.7%
1/13 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/1 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/17 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/2 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/7 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/2 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
|
Gastrointestinal disorders
Nausea
|
36.4%
4/11 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
22.2%
2/9 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
38.5%
5/13 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
100.0%
1/1 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/17 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/2 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/7 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
50.0%
1/2 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
|
Gastrointestinal disorders
Oral pain
|
0.00%
0/11 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/9 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/13 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/1 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/17 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/2 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/7 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
50.0%
1/2 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
|
Gastrointestinal disorders
Proctalgia
|
0.00%
0/11 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
11.1%
1/9 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/13 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/1 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/17 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/2 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/7 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/2 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
|
Gastrointestinal disorders
Vomiting
|
36.4%
4/11 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/9 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
15.4%
2/13 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/1 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
17.6%
3/17 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/2 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/7 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/2 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
|
General disorders
Asthenia
|
9.1%
1/11 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/9 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/13 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/1 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/17 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/2 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/7 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/2 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
|
General disorders
Chills
|
0.00%
0/11 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
11.1%
1/9 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
7.7%
1/13 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/1 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/17 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
50.0%
1/2 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
14.3%
1/7 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/2 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
|
General disorders
Fatigue
|
27.3%
3/11 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
44.4%
4/9 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
46.2%
6/13 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/1 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
11.8%
2/17 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/2 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/7 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
100.0%
2/2 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
|
General disorders
Mucosal inflammation
|
0.00%
0/11 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/9 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
7.7%
1/13 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/1 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/17 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/2 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/7 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/2 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
|
General disorders
Non-cardiac chest pain
|
0.00%
0/11 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/9 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
7.7%
1/13 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/1 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/17 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/2 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/7 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/2 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
|
General disorders
Oedema
|
0.00%
0/11 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/9 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/13 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/1 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
5.9%
1/17 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/2 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/7 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/2 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
|
General disorders
Oedema peripheral
|
0.00%
0/11 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
11.1%
1/9 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
7.7%
1/13 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/1 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
5.9%
1/17 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/2 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
14.3%
1/7 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
50.0%
1/2 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
|
General disorders
Pain
|
9.1%
1/11 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/9 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
7.7%
1/13 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/1 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
11.8%
2/17 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/2 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/7 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/2 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
|
General disorders
Physical deconditioning
|
0.00%
0/11 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/9 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/13 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/1 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
5.9%
1/17 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/2 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/7 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/2 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
|
General disorders
Pyrexia
|
9.1%
1/11 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
22.2%
2/9 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/13 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
100.0%
1/1 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
11.8%
2/17 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/2 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/7 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
50.0%
1/2 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
|
General disorders
Suprapubic pain
|
0.00%
0/11 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/9 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/13 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
100.0%
1/1 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/17 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/2 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/7 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/2 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
|
General disorders
Swelling
|
0.00%
0/11 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/9 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
7.7%
1/13 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/1 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/17 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/2 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/7 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/2 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
|
Hepatobiliary disorders
Hyperbilirubinaemia
|
18.2%
2/11 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
11.1%
1/9 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/13 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/1 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/17 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/2 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/7 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/2 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
|
Hepatobiliary disorders
Jaundice
|
0.00%
0/11 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/9 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/13 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/1 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
5.9%
1/17 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/2 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/7 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/2 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
|
Hepatobiliary disorders
Ocular icterus
|
0.00%
0/11 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/9 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/13 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/1 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
5.9%
1/17 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/2 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/7 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/2 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
|
Immune system disorders
Cytokine release syndrome
|
0.00%
0/11 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
33.3%
3/9 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
15.4%
2/13 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
100.0%
1/1 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
41.2%
7/17 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
100.0%
2/2 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
14.3%
1/7 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
50.0%
1/2 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
|
Immune system disorders
Hypogammaglobulinaemia
|
9.1%
1/11 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
11.1%
1/9 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/13 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/1 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/17 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/2 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/7 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/2 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
|
Infections and infestations
Bronchitis
|
0.00%
0/11 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
11.1%
1/9 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/13 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/1 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/17 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/2 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/7 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/2 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
|
Infections and infestations
COVID-19
|
0.00%
0/11 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/9 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/13 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/1 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
5.9%
1/17 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/2 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
14.3%
1/7 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/2 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
|
Infections and infestations
Candida infection
|
0.00%
0/11 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/9 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
15.4%
2/13 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/1 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/17 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/2 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/7 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/2 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
|
Infections and infestations
Conjunctivitis
|
0.00%
0/11 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/9 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/13 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/1 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
5.9%
1/17 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/2 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/7 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/2 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
|
Infections and infestations
Cytomegalovirus infection reactivation
|
0.00%
0/11 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/9 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/13 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/1 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
5.9%
1/17 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/2 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/7 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/2 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
|
Infections and infestations
Pneumonia
|
9.1%
1/11 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
22.2%
2/9 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/13 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
100.0%
1/1 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/17 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/2 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
14.3%
1/7 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/2 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
|
Infections and infestations
Sinusitis
|
0.00%
0/11 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/9 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
15.4%
2/13 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/1 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/17 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/2 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/7 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/2 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
|
Infections and infestations
Upper respiratory tract infection
|
9.1%
1/11 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/9 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/13 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/1 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/17 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/2 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/7 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/2 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
|
Infections and infestations
Urinary tract infection
|
0.00%
0/11 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
11.1%
1/9 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/13 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/1 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
5.9%
1/17 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/2 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/7 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/2 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
|
Infections and infestations
Viral infection
|
0.00%
0/11 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/9 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
7.7%
1/13 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/1 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/17 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/2 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/7 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/2 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
|
Infections and infestations
Vulvitis
|
0.00%
0/11 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/9 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
7.7%
1/13 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/1 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/17 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/2 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/7 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/2 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
|
Injury, poisoning and procedural complications
Contusion
|
0.00%
0/11 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/9 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
15.4%
2/13 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/1 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
11.8%
2/17 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
50.0%
1/2 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/7 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/2 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
|
Injury, poisoning and procedural complications
Epicondylitis
|
0.00%
0/11 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
11.1%
1/9 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/13 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/1 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/17 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/2 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/7 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/2 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
|
Injury, poisoning and procedural complications
Fall
|
0.00%
0/11 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/9 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/13 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
100.0%
1/1 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
5.9%
1/17 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/2 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/7 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/2 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
|
Injury, poisoning and procedural complications
Infusion related reaction
|
0.00%
0/11 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/9 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
7.7%
1/13 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/1 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/17 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/2 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/7 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/2 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
|
Injury, poisoning and procedural complications
Vascular access site bruising
|
0.00%
0/11 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
11.1%
1/9 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/13 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/1 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/17 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/2 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/7 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/2 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
|
Investigations
Aspartate aminotransferase increased
|
9.1%
1/11 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/9 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
7.7%
1/13 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/1 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/17 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/2 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
14.3%
1/7 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/2 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
|
Investigations
Alanine aminotransferase increased
|
9.1%
1/11 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/9 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
7.7%
1/13 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/1 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
5.9%
1/17 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/2 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/7 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/2 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
|
Investigations
Blood alkaline phosphatase increased
|
9.1%
1/11 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/9 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/13 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/1 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/17 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/2 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/7 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/2 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
|
Investigations
Blood bilirubin increased
|
0.00%
0/11 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/9 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/13 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/1 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
5.9%
1/17 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/2 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/7 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/2 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
|
Investigations
Blood creatinine increased
|
0.00%
0/11 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/9 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
7.7%
1/13 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/1 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
5.9%
1/17 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/2 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/7 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/2 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
|
Investigations
Blood uric acid increased
|
0.00%
0/11 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/9 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/13 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/1 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/17 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/2 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
14.3%
1/7 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/2 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
|
Investigations
International normalised ratio increased
|
0.00%
0/11 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/9 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
7.7%
1/13 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/1 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/17 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/2 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
14.3%
1/7 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/2 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
|
Investigations
Liver function test increased
|
0.00%
0/11 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/9 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
7.7%
1/13 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/1 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/17 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/2 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/7 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/2 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
|
Investigations
Lymphocyte count decreased
|
0.00%
0/11 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/9 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/13 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/1 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
58.8%
10/17 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/2 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
14.3%
1/7 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
50.0%
1/2 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
|
Investigations
Neutrophil count decreased
|
0.00%
0/11 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/9 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/13 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/1 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
64.7%
11/17 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/2 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
42.9%
3/7 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
100.0%
2/2 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
|
Investigations
Platelet count decreased
|
0.00%
0/11 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/9 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/13 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/1 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
52.9%
9/17 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/2 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
14.3%
1/7 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
100.0%
2/2 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
|
Investigations
Prostatic specific antigen increased
|
0.00%
0/11 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/9 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
7.7%
1/13 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/1 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/17 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/2 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/7 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/2 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
|
Investigations
Weight decreased
|
0.00%
0/11 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
11.1%
1/9 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
15.4%
2/13 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/1 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/17 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/2 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/7 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/2 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
|
Investigations
White blood cell count decreased
|
0.00%
0/11 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/9 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/13 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/1 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
70.6%
12/17 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/2 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
28.6%
2/7 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
50.0%
1/2 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
|
Metabolism and nutrition disorders
Decreased appetite
|
0.00%
0/11 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
22.2%
2/9 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
23.1%
3/13 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
100.0%
1/1 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
29.4%
5/17 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/2 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/7 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/2 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
|
Metabolism and nutrition disorders
Dehydration
|
0.00%
0/11 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/9 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
7.7%
1/13 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/1 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
5.9%
1/17 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
50.0%
1/2 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
14.3%
1/7 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/2 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
|
Metabolism and nutrition disorders
Hypercalcaemia
|
0.00%
0/11 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/9 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/13 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/1 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/17 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
50.0%
1/2 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/7 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/2 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
|
Metabolism and nutrition disorders
Hyperglycaemia
|
0.00%
0/11 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
11.1%
1/9 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/13 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/1 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/17 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/2 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/7 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/2 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
|
Metabolism and nutrition disorders
Hyperkalaemia
|
0.00%
0/11 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/9 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
7.7%
1/13 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/1 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/17 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/2 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/7 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/2 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
|
Metabolism and nutrition disorders
Hypertriglyceridaemia
|
9.1%
1/11 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/9 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/13 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/1 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/17 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/2 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/7 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/2 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
|
Metabolism and nutrition disorders
Hyperuricaemia
|
0.00%
0/11 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/9 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/13 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/1 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
11.8%
2/17 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/2 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/7 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/2 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
|
Metabolism and nutrition disorders
Hypoalbuminaemia
|
0.00%
0/11 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/9 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
7.7%
1/13 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/1 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/17 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/2 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/7 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/2 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
|
Metabolism and nutrition disorders
Hypocalcaemia
|
9.1%
1/11 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/9 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
7.7%
1/13 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
100.0%
1/1 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
5.9%
1/17 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/2 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/7 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/2 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
|
Metabolism and nutrition disorders
Hypokalaemia
|
27.3%
3/11 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
22.2%
2/9 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
7.7%
1/13 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
100.0%
1/1 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
11.8%
2/17 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
50.0%
1/2 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
14.3%
1/7 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/2 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
|
Metabolism and nutrition disorders
Hypomagnesaemia
|
18.2%
2/11 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
44.4%
4/9 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
7.7%
1/13 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/1 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
11.8%
2/17 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/2 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
14.3%
1/7 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/2 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
|
Metabolism and nutrition disorders
Hyponatraemia
|
9.1%
1/11 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/9 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
7.7%
1/13 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/1 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/17 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/2 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/7 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/2 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
|
Metabolism and nutrition disorders
Hypophosphataemia
|
9.1%
1/11 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
33.3%
3/9 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
23.1%
3/13 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
100.0%
1/1 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
5.9%
1/17 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
50.0%
1/2 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/7 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/2 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
|
Metabolism and nutrition disorders
Tumour lysis syndrome
|
0.00%
0/11 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
11.1%
1/9 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/13 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/1 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/17 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/2 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/7 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/2 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
|
Musculoskeletal and connective tissue disorders
Arthralgia
|
9.1%
1/11 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
22.2%
2/9 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
23.1%
3/13 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
100.0%
1/1 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
5.9%
1/17 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
50.0%
1/2 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/7 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/2 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
|
Musculoskeletal and connective tissue disorders
Back pain
|
9.1%
1/11 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
11.1%
1/9 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
30.8%
4/13 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
100.0%
1/1 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/17 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/2 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
14.3%
1/7 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/2 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
|
Musculoskeletal and connective tissue disorders
Bone pain
|
0.00%
0/11 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/9 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
7.7%
1/13 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/1 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/17 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/2 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
14.3%
1/7 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
50.0%
1/2 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
|
Musculoskeletal and connective tissue disorders
Coccydynia
|
0.00%
0/11 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/9 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
7.7%
1/13 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/1 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/17 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/2 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/7 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/2 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
|
Musculoskeletal and connective tissue disorders
Joint swelling
|
0.00%
0/11 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/9 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
7.7%
1/13 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/1 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/17 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/2 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/7 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/2 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
|
Musculoskeletal and connective tissue disorders
Limb discomfort
|
0.00%
0/11 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/9 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
7.7%
1/13 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/1 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/17 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/2 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/7 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/2 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
|
Musculoskeletal and connective tissue disorders
Mastication disorder
|
0.00%
0/11 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/9 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
7.7%
1/13 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/1 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/17 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/2 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/7 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/2 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
|
Musculoskeletal and connective tissue disorders
Muscle spasms
|
0.00%
0/11 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
11.1%
1/9 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/13 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/1 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/17 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/2 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/7 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/2 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
|
Musculoskeletal and connective tissue disorders
Muscular weakness
|
9.1%
1/11 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
11.1%
1/9 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
15.4%
2/13 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/1 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
17.6%
3/17 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
50.0%
1/2 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/7 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
50.0%
1/2 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
|
Musculoskeletal and connective tissue disorders
Musculoskeletal chest pain
|
18.2%
2/11 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/9 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/13 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/1 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
5.9%
1/17 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/2 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/7 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/2 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
|
Musculoskeletal and connective tissue disorders
Musculoskeletal discomfort
|
0.00%
0/11 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
11.1%
1/9 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/13 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/1 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/17 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/2 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/7 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/2 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
|
Musculoskeletal and connective tissue disorders
Myalgia
|
0.00%
0/11 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/9 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
7.7%
1/13 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
100.0%
1/1 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/17 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/2 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
14.3%
1/7 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/2 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
|
Musculoskeletal and connective tissue disorders
Pain in extremity
|
0.00%
0/11 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/9 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
7.7%
1/13 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
100.0%
1/1 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/17 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/2 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/7 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/2 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
|
Musculoskeletal and connective tissue disorders
Pain in jaw
|
0.00%
0/11 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/9 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/13 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/1 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/17 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/2 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
14.3%
1/7 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/2 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Colorectal adenoma
|
0.00%
0/11 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
11.1%
1/9 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/13 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/1 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/17 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/2 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/7 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/2 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
|
Nervous system disorders
Amnesia
|
0.00%
0/11 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/9 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/13 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/1 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
5.9%
1/17 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/2 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/7 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/2 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
|
Nervous system disorders
Brain fog
|
0.00%
0/11 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/9 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
7.7%
1/13 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/1 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/17 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/2 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/7 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/2 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
|
Nervous system disorders
Dizziness
|
0.00%
0/11 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
11.1%
1/9 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
38.5%
5/13 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
100.0%
1/1 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
17.6%
3/17 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/2 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
14.3%
1/7 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/2 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
|
Nervous system disorders
Dysarthria
|
0.00%
0/11 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/9 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
15.4%
2/13 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/1 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/17 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/2 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/7 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/2 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
|
Nervous system disorders
Haemorrhage intracranial
|
0.00%
0/11 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/9 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
7.7%
1/13 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/1 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/17 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/2 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/7 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/2 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
|
Nervous system disorders
Headache
|
9.1%
1/11 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/9 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
7.7%
1/13 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/1 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/17 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/2 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
14.3%
1/7 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
50.0%
1/2 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
|
Nervous system disorders
Hypoaesthesia
|
0.00%
0/11 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
11.1%
1/9 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/13 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/1 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/17 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/2 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/7 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/2 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
|
Nervous system disorders
Hyporeflexia
|
0.00%
0/11 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/9 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
7.7%
1/13 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/1 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/17 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/2 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/7 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/2 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
|
Nervous system disorders
Hypotonia
|
0.00%
0/11 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
11.1%
1/9 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/13 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/1 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/17 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/2 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/7 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/2 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
|
Nervous system disorders
Intention tremor
|
0.00%
0/11 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/9 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
7.7%
1/13 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/1 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/17 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/2 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/7 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/2 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
|
Nervous system disorders
Lethargy
|
0.00%
0/11 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/9 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/13 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
100.0%
1/1 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/17 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/2 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/7 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/2 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
|
Nervous system disorders
Memory impairment
|
0.00%
0/11 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
11.1%
1/9 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/13 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/1 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/17 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/2 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/7 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/2 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
|
Nervous system disorders
Neuralgia
|
0.00%
0/11 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
11.1%
1/9 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/13 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/1 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/17 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/2 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/7 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/2 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
|
Nervous system disorders
Neuropathy peripheral
|
0.00%
0/11 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/9 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
7.7%
1/13 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/1 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/17 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/2 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/7 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/2 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
|
Nervous system disorders
Neurotoxicity
|
0.00%
0/11 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
11.1%
1/9 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
15.4%
2/13 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
100.0%
1/1 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
17.6%
3/17 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
50.0%
1/2 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/7 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/2 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
|
Nervous system disorders
Nystagmus
|
9.1%
1/11 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/9 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/13 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/1 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/17 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/2 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
14.3%
1/7 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/2 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
|
Nervous system disorders
Peripheral motor neuropathy
|
0.00%
0/11 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
11.1%
1/9 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/13 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/1 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/17 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/2 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/7 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/2 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
|
Nervous system disorders
Peroneal nerve palsy
|
0.00%
0/11 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/9 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/13 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/1 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
5.9%
1/17 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/2 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/7 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/2 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
|
Nervous system disorders
Resting tremor
|
0.00%
0/11 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/9 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
7.7%
1/13 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/1 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/17 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/2 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/7 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/2 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
|
Nervous system disorders
Restless legs syndrome
|
0.00%
0/11 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
11.1%
1/9 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/13 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/1 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/17 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/2 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/7 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/2 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
|
Nervous system disorders
Syncope
|
0.00%
0/11 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/9 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/13 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/1 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/17 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
50.0%
1/2 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/7 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/2 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
|
Nervous system disorders
Tremor
|
0.00%
0/11 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
11.1%
1/9 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
15.4%
2/13 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/1 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
11.8%
2/17 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/2 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/7 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
50.0%
1/2 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
|
Psychiatric disorders
Agitation
|
0.00%
0/11 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
11.1%
1/9 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
7.7%
1/13 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
100.0%
1/1 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/17 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/2 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/7 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/2 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
|
Psychiatric disorders
Anxiety
|
0.00%
0/11 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/9 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
7.7%
1/13 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/1 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
5.9%
1/17 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/2 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/7 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/2 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
|
Psychiatric disorders
Confusional state
|
0.00%
0/11 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/9 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
7.7%
1/13 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
100.0%
1/1 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
5.9%
1/17 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/2 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
14.3%
1/7 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/2 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
|
Psychiatric disorders
Delirium
|
0.00%
0/11 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/9 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
7.7%
1/13 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
100.0%
1/1 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/17 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/2 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/7 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/2 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
|
Psychiatric disorders
Depressed mood
|
0.00%
0/11 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
11.1%
1/9 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/13 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/1 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/17 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/2 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/7 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/2 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
|
Psychiatric disorders
Depression
|
0.00%
0/11 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/9 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
7.7%
1/13 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
100.0%
1/1 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/17 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/2 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/7 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/2 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
|
Psychiatric disorders
Insomnia
|
18.2%
2/11 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/9 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/13 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/1 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
17.6%
3/17 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/2 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/7 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
50.0%
1/2 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
|
Psychiatric disorders
Libido decreased
|
0.00%
0/11 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/9 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
7.7%
1/13 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/1 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/17 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/2 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/7 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/2 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
|
Renal and urinary disorders
Acute kidney injury
|
0.00%
0/11 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/9 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
7.7%
1/13 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/1 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/17 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
50.0%
1/2 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/7 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/2 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
|
Renal and urinary disorders
Chronic kidney disease
|
0.00%
0/11 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
11.1%
1/9 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/13 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/1 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/17 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/2 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/7 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/2 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
|
Renal and urinary disorders
Haematuria
|
0.00%
0/11 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/9 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
7.7%
1/13 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/1 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/17 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/2 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/7 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/2 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
|
Renal and urinary disorders
Micturition urgency
|
0.00%
0/11 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/9 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/13 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
100.0%
1/1 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/17 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/2 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/7 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/2 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
|
Renal and urinary disorders
Pollakiuria
|
0.00%
0/11 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/9 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
7.7%
1/13 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/1 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/17 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/2 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/7 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/2 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
|
Renal and urinary disorders
Renal failure
|
0.00%
0/11 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/9 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/13 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
100.0%
1/1 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/17 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/2 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/7 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/2 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
|
Renal and urinary disorders
Urinary retention
|
0.00%
0/11 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/9 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/13 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/1 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
5.9%
1/17 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/2 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/7 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/2 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
|
Renal and urinary disorders
Urinary tract pain
|
0.00%
0/11 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/9 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
7.7%
1/13 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
100.0%
1/1 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/17 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/2 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/7 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/2 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
|
Renal and urinary disorders
Urine abnormality
|
0.00%
0/11 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
11.1%
1/9 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/13 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/1 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/17 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/2 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/7 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/2 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
|
Reproductive system and breast disorders
Benign prostatic hyperplasia
|
0.00%
0/11 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/9 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
7.7%
1/13 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/1 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/17 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/2 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/7 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/2 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
|
Respiratory, thoracic and mediastinal disorders
Cough
|
9.1%
1/11 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
44.4%
4/9 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
15.4%
2/13 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/1 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
5.9%
1/17 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
50.0%
1/2 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
14.3%
1/7 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/2 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
|
Respiratory, thoracic and mediastinal disorders
Diaphragmalgia
|
0.00%
0/11 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
11.1%
1/9 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/13 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/1 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/17 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/2 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/7 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/2 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
|
Respiratory, thoracic and mediastinal disorders
Dysphonia
|
9.1%
1/11 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/9 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
15.4%
2/13 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/1 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/17 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/2 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/7 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/2 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
|
Respiratory, thoracic and mediastinal disorders
Dyspnoea
|
0.00%
0/11 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/9 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
7.7%
1/13 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/1 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
11.8%
2/17 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/2 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
14.3%
1/7 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/2 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
|
Respiratory, thoracic and mediastinal disorders
Dyspnoea exertional
|
0.00%
0/11 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
22.2%
2/9 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/13 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/1 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/17 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/2 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/7 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/2 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
|
Respiratory, thoracic and mediastinal disorders
Epistaxis
|
0.00%
0/11 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/9 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
7.7%
1/13 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/1 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/17 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/2 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/7 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/2 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
|
Respiratory, thoracic and mediastinal disorders
Hypoxia
|
0.00%
0/11 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
11.1%
1/9 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/13 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
100.0%
1/1 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
11.8%
2/17 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/2 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/7 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/2 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
|
Respiratory, thoracic and mediastinal disorders
Nasal discomfort
|
18.2%
2/11 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
11.1%
1/9 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/13 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/1 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/17 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/2 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/7 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/2 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
|
Respiratory, thoracic and mediastinal disorders
Oropharyngeal pain
|
9.1%
1/11 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/9 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
7.7%
1/13 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/1 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
5.9%
1/17 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
50.0%
1/2 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/7 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/2 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
|
Respiratory, thoracic and mediastinal disorders
Pleural effusion
|
0.00%
0/11 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
11.1%
1/9 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/13 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/1 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
17.6%
3/17 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/2 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/7 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/2 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
|
Respiratory, thoracic and mediastinal disorders
Pneumothorax
|
0.00%
0/11 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
11.1%
1/9 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/13 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/1 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/17 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/2 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/7 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/2 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
|
Respiratory, thoracic and mediastinal disorders
Productive cough
|
9.1%
1/11 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/9 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/13 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/1 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/17 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/2 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/7 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/2 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
|
Respiratory, thoracic and mediastinal disorders
Rhinitis allergic
|
0.00%
0/11 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/9 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
7.7%
1/13 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/1 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/17 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/2 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/7 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/2 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
|
Respiratory, thoracic and mediastinal disorders
Rhinorrhoea
|
9.1%
1/11 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/9 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
7.7%
1/13 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/1 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/17 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/2 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/7 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/2 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
|
Respiratory, thoracic and mediastinal disorders
Tachypnoea
|
0.00%
0/11 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/9 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
7.7%
1/13 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/1 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/17 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/2 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
14.3%
1/7 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/2 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
|
Respiratory, thoracic and mediastinal disorders
Upper-airway cough syndrome
|
0.00%
0/11 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/9 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
7.7%
1/13 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/1 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/17 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/2 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/7 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/2 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
|
Respiratory, thoracic and mediastinal disorders
Wheezing
|
0.00%
0/11 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
11.1%
1/9 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
7.7%
1/13 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/1 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/17 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/2 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/7 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/2 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
|
Skin and subcutaneous tissue disorders
Alopecia
|
0.00%
0/11 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/9 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/13 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/1 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/17 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/2 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
14.3%
1/7 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/2 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
|
Skin and subcutaneous tissue disorders
Dermatitis acneiform
|
0.00%
0/11 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/9 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
7.7%
1/13 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/1 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/17 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/2 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/7 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/2 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
|
Skin and subcutaneous tissue disorders
Dry skin
|
0.00%
0/11 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/9 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
7.7%
1/13 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/1 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/17 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/2 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/7 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/2 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
|
Skin and subcutaneous tissue disorders
Ecchymosis
|
0.00%
0/11 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/9 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
15.4%
2/13 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/1 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/17 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/2 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/7 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/2 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
|
Skin and subcutaneous tissue disorders
Erythema
|
0.00%
0/11 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/9 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
7.7%
1/13 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/1 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/17 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/2 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
14.3%
1/7 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/2 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
|
Skin and subcutaneous tissue disorders
Hyperhidrosis
|
0.00%
0/11 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
11.1%
1/9 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/13 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/1 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/17 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/2 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/7 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/2 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
|
Skin and subcutaneous tissue disorders
Night sweats
|
0.00%
0/11 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
11.1%
1/9 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
15.4%
2/13 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/1 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
5.9%
1/17 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/2 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/7 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/2 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
|
Skin and subcutaneous tissue disorders
Pruritus
|
0.00%
0/11 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/9 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
7.7%
1/13 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/1 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
11.8%
2/17 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/2 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/7 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/2 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
|
Skin and subcutaneous tissue disorders
Rash
|
18.2%
2/11 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
11.1%
1/9 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
7.7%
1/13 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/1 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/17 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/2 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/7 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/2 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
|
Skin and subcutaneous tissue disorders
Rash maculo-papular
|
0.00%
0/11 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/9 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/13 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/1 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/17 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/2 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
14.3%
1/7 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/2 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
|
Skin and subcutaneous tissue disorders
Rash pruritic
|
0.00%
0/11 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/9 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
7.7%
1/13 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/1 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/17 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/2 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/7 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/2 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
|
Skin and subcutaneous tissue disorders
Seborrhoeic dermatitis
|
0.00%
0/11 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/9 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/13 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/1 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
5.9%
1/17 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/2 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/7 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/2 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
|
Vascular disorders
Aneurysm
|
0.00%
0/11 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
11.1%
1/9 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/13 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/1 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/17 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/2 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/7 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/2 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
|
Vascular disorders
Bloody discharge
|
9.1%
1/11 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/9 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/13 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/1 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/17 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/2 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/7 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/2 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
|
Vascular disorders
Deep vein thrombosis
|
0.00%
0/11 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/9 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
7.7%
1/13 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/1 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
5.9%
1/17 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/2 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/7 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/2 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
|
Vascular disorders
Embolism
|
0.00%
0/11 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/9 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/13 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/1 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/17 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/2 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
14.3%
1/7 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/2 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
|
Vascular disorders
Flushing
|
0.00%
0/11 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/9 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
7.7%
1/13 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/1 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/17 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/2 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/7 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/2 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
|
Vascular disorders
Haematoma
|
0.00%
0/11 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/9 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
7.7%
1/13 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/1 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
5.9%
1/17 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/2 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/7 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/2 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
|
Vascular disorders
Hypertension
|
9.1%
1/11 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/9 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/13 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/1 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
17.6%
3/17 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/2 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/7 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/2 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
|
Vascular disorders
Hypotension
|
0.00%
0/11 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
22.2%
2/9 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
15.4%
2/13 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
100.0%
1/1 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
5.9%
1/17 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/2 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/7 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
100.0%
2/2 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
|
Vascular disorders
Orthostatic hypotension
|
0.00%
0/11 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
11.1%
1/9 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
7.7%
1/13 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/1 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/17 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/2 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/7 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/2 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
|
Metabolism and nutrition disorders
Appetite disorder
|
0.00%
0/11 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/9 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/13 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/1 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
5.9%
1/17 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/2 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/7 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/2 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
|
Nervous system disorders
Paraesthesia
|
0.00%
0/11 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/9 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
7.7%
1/13 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/1 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/17 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/2 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/7 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/2 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
|
Vascular disorders
Thrombophlebitis
|
0.00%
0/11 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/9 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
7.7%
1/13 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/1 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/17 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/2 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/7 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
0.00%
0/2 • Participants were assessed for All-Cause Mortality from the date of leukapheresis until study completion (assessed up to approximately 62 months). SAEs and Other AEs were assessed from leukapheresis to 90 days after last dose of study therapy (an average of 7.5 months up until a max of 10.5 months).
All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that underwent leukapheresis and may or may not have received at least 1 dose of JCAR017. Data is shown per cohort.
|
Additional Information
Bristol-Myers Squibb Study Director
Bristol-Myers Squibb
Phone: Please email
Email: [email protected]
Results disclosure agreements
- Principal investigator is a sponsor employee Bristol-Myers Squibb Co. agreements with investigators vary; constant is our right to embargo communications regarding trial results prior to public release for a period ≤60 days from submittal for review. We will not prohibit investigators from publishing but will prohibit the disclosure of previously undisclosed confidential information other than study results, and request postponement of single-center publications until after disclosure of the clinical trial's primary publication.
- Publication restrictions are in place
Restriction type: OTHER